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ABSTRACT OF DISSERTATION

A COMPARISON OF UPPER EXTREMITY FUNCTION BETWEEN FEMALE
BREAST CANCER SURVIVORS AND HEALTHY CONTROLS: TYPICAL SELFREPORT OF FUNCTION, MOTION, STRENGTH AND MUSCULAR ENDURANCE

Many women who have experienced breast cancer (BC) report continued
impairments in upper extremity (UE) function beyond the time required for normal
healing after surgical treatment. Most research supporting this has not made comparisons
between survivors of breast cancer (BCS) to a sample of healthy women. This lack of
comparison to a healthy cohort prevents an understanding of whether continued deficits
in UE function are due to normal aging or the BC treatment.
The purpose of this research was to compare quality of life (QOL) and UE
function among long term breast cancer survivors and similar aged women without
cancer. Both self-report and objective measurements of UE function were used to create
an understanding of UE functional abilities in both populations.
Data on self-reported QOL and UE function, ROM, strength, and muscular
endurance were collected on 79 healthy women ages 30-69, stratified by decade.
Comparisons between decades and between dominant and non-dominant limbs were
made. Findings supported no effect of aging on measures, and that dominance does
affect some objective measures of motion, strength, and muscular endurance.
A group of 42 survivors of breast cancer (BCS) were compared to the data from
healthy controls on the same measures. BCS reported lower levels of QOL and UE
function, and demonstrated less motion and strength than the healthy cohort, particularly
when cancer occurred on the non-dominant limb. The values of the measures, however,
are not clinically relevant, and reveal that BCS 6 years after treatment recover UE
function to levels similar to healthy controls.
In view of a lack of clinically feasible measures of UE muscular endurance, a new
test to assess this was designed and implemented: the modified Upper Body Strength and
Endurance test (mUBSE). It was believed this new test would be less variable than the

Functional Impairment Test – Hand and Neck, Shoulder, Arm – FIT-HaNSA. Seventeen
BCS and 17 matched controls were compared on the mUBSE and FIT-HaNSA. Findings
were similar for both tests. Furthermore, BCS who are 6 years post BC treatment appear
to recover muscular endurance levels to normal ranges.

KEYWORDS: Breast cancer, quality of life, upper extremity function, range of motion
and strength, muscular endurance
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CHAPTER ONE
Breast cancer is the most common non-skin cancer among women, with a lifetime risk of
1 in 8.1 Approximately 226,870 women will be diagnosed with breast cancer (BC) in
2012 alone.2 Over the last 25 years, survival rates have increased to 90%; current
estimates are that over 2.5 million women are living with BC.1 As the number of women
living beyond diagnosis and treatment of BC has climbed, the focus of research and
intervention is expanding to include quality of life (QOL) issues for survivors.
Activity limitations and participation restrictions among survivors of breast
cancer (BCS) can be attributed to physical declines reported on QOL scales. Physical
function scores decline the greatest immediately following surgical treatment for breast
cancer, but remain below baseline 6-104 weeks after treatment.3,4 These deficits are
greater among women who undergo more involved interventions such as axillary lymph
node dissection or mastectomy surgeries, or axillary radiation, than the less invasive
lumpectomy or sentinel node biopsy.5,6
The link between activity limitations and participation restrictions, and QOL may
be explained by changes in upper extremity (UE) function after BC treatment. Full UE
function is dependent upon adequate motion, strength, and muscular endurance to
complete a particular task.7 Women diagnosed with BC frequently have upper extremity
functional deficits associated with treatment including loss in motion and strength in the
arm, resulting in activity limitations.8-13 Less is known about the extent of change in
muscular endurance and its impact on UE function.14-16
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Self-Report of Function of BCS
Researchers have provided evidence of moderate to high levels of UE selfreported disability among women treated for BC. In a long term study following 188
BCS, the Disabilities of the Arm, Shoulder, and Hand (DASH) was used to determine the
extent of upper body functional impairment.17 Scores of greater than 20 on the DASH
were categorized as poor upper body function. At 6 months following BC treatment,
25.6% of BCS scored greater than 20, and at a 6 year follow-up, 21.1% continued to
score greater than 20.17 Other studies examining the self-reported level of UE function
have documented mean DASH scores ranging from 24 to 32 in BCS 1-360 months
following treatment.18,19 This continued report of UE functional impairment more than 5
years after BC treatment suggests that this is an issue that the medical community should
address during the acute recovery phase to facilitate resumption of normal levels of
function.
Understanding how the level of self-reported function among long term BCS
compares to a healthy population may clarify whether persistent functional disability is
due to BC treatment or occurs with normal aging. One such study which used the DASH
to compare self-reported levels of disability of a group of BCS at 6 months following
treatment to a healthy control group found significantly more disability in the BC group
(19.4±17) than the control group (1.6±1.7).9 This comparison between BCS and a group
of healthy women has not been done for BCS more than 12 months beyond BC treatment.
To better understand persistent functional disability however, it is important to know
whether the report of disability long term is due to BC treatment or normal aging.
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Objective Measures of UE Function among Survivors of BC
Range of motion (ROM) and strength are integral to normal UE function. These
objective measures of UE function have been examined in BCS within the first year
following diagnosis and treatment. Diminished motion8,11,14,20 and strength8,14,16 of the
involved extremity have been documented in comparison to the non-involved side. The
same limitation exists for these data as the self-reported function in that the changes
seen compared to the contralateral limb may not be long term, but rather due to the
necessary healing time required following surgical and radiation treatments.
Furthermore, limited data exist comparing the UE function among BCS in the short term
to a population of healthy controls. One study has compared UE function of 24 BCS less
than 6 months from surgical intervention to matched controls, and reported significant
but small motion deficits ranging from 5-11°, and moderate strength deficits of greater
than 20%.9 It is unknown if these deficits persist beyond 6 months when compared to a
healthy cohort. A study comparing long term BC survivors to a similar population of
healthy controls would help to determine whether these deficits are present beyond the
first year following BC treatment, and provide information on the long term effects of
breast cancer treatment on UE function.
The prevalence of fatigue associated with BC treatments has been as high as 6199% in all BCS,21 with 41% of BCS reporting fatigue 2-5 years after diagnosis.22 This
near universal complaint would suggest that muscular endurance has not been restored
following BC interventions. Furthermore, diminished muscular endurance can impact UE
function.7 Muscular endurance is an essential component of UE function, yet has been
minimally studied among BCS. Two studies have examined muscular endurance of the
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involved UE compared to the contralateral limb in BCS. Within the first 6 months of
treatment among BCS undergoing surgical treatment, muscular endurance was altered by
20% in the involved limb.14 In another study of study of 40 BCS with a mean duration
since treatment of 28 months, no deficits in muscular endurance were found in the
involved extremity when compared to the non-involved side.16 These findings suggest
that BCS recover muscular endurance over time however, this latter study may have
biased recruitment of muscle fibers toward fast twitch, calling into question whether the
test actually assessed muscular endurance. More importantly, neither study made a
comparison to a healthy population; therefore a determination cannot be made whether an
inequality in muscular endurance is due to an inherent difference between arms, due to
aging, or is a result of pathology.
Problem
Quality of life is often compromised following breast cancer treatment in the short
term, and is commonly associated with UE functional deficits. Long term deficits in
motion and strength have been reported following treatment for BC, although the
prevalence of deficits declines from the short term.10,12,15,20 Furthermore, questions arise
regarding the extent of the deficits which persist beyond the first year after treatment and
how these may affect overall UE function, but it is reasonable to expect these deficits are
sustained in the long term to some degree. No study has directly compared healthy
women to BCS using objective measures of upper body motion, strength, or muscular
endurance at 12 months or more after surgical intervention. Comparison to a healthy
population allows a determination whether UE deficits are due to cancer and subsequent
treatments, or due to the natural aging process.
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Purpose
The primary purpose of this research is to compare quality of life and UE function
among long term breast cancer survivors and similar aged women without cancer. Both
self-report and objective measurements of UE function are used to create an
understanding of UE functional abilities in both populations.
Hypotheses
1a) Self-report of QOL and UE function will be lower among a group of BCS compared
to healthy controls of the same age.
1b) Motion, strength, and muscular endurance will be less on the involved limb in women
with BC compared to same limb in women without BC.
1c) Motion, strength, and muscular endurance will be less on the involved limb than the
non-involved limb in women treated for BC.
The second purpose is to determine if UE function declines across the normal
aging process, and whether ROM, strength, and muscular endurance differ based on limb
dominance.
Hypotheses
2a) Motion, strength, and endurance measurements will decline with aging among a
healthy population of women stratified by decade from 30’s to 60’s.
2b) The dominant limb of healthy women ages 30-69 will demonstrate greater strength
and muscular endurance than the non-dominant limb.
2c) The dominant limb of healthy women ages 30-69 will demonstrate decreased
shoulder mobility than the non-dominant limb.
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The third aim of this dissertation is to investigate and compare clinical measures
of muscular endurance in order to identify a measure that has good responsiveness and
minimal ceiling effects.
Hypothesis
3) The modified Upper Body Strength and Endurance test (mUBSE) will be a less
variable measure of muscular endurance than the FIT-HaNSA.
Operational Definitions
For the purposes of this study, the following definitions were used:
Estimated 1 repetition maximum (1RM) is a submaximal repetition test used to determine
a 1RM value. Each participant was given a heavy load, and the number of repetitions
correctly performed was counted. The estimation is based on the following formula
where x is the number of repetitions completed:23
Estimated 1RM = weight lifted/(1.0278-.0278x)
Short term effects are deficits in self-reported QOL and UE function, shoulder motion,
strength, muscular endurance, present immediately after surgical treatment and which
resolve within 12 months.
Long term effects are said deficits lasting greater than 12 months.
Outcome measures:
Range of Motion: Range of motion measured with a goniometer has adequate to good
intra-rater reliability,24 reported by various authors with ICCs ranging .53-.98.25,26
Goniometric landmarks were used in this study, however, measurement of shoulder
flexion, external rotation, and hand behind back (HBB) was be completed using digital
photography and software to calculate angles and distances. The (HBB) measure is the
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distance in centimeters from the C7 spinous process to the spinous process in line with
the tip of the thumb when the hand is reached behind the back as high as possible.27
Strength: Strength of shoulder flexors, internal and external rotators as measured with a
mean maximal voluntary isometric contraction (MVIC) using hand-held dynamometry
was completed.7 Strength was then normalized to body weight and reported as a
percentage of body weight in order to make comparisons among individuals clearer.
Muscular Endurance: One measure of muscular endurance is Functional Impairment
Test - Hand, and Neck, Shoulder, Arm (FIT-HaNSA),28,29 which measures the duration
of UE lifting and manipulation tasks. A second test of muscular endurance used is a
modified Upper Body Strength and Endurance Test (mUBSE), patterned after the Upper
Body Strength and Endurance Test.14,15 In the mUBSE, the participant repetitively lifted
50% of her estimated 1RM until one of 4 stopping criteria were met:
1. Participant could no longer continue lifting weight
2. Participant could not reach her maximum high point of elevation 2 times
consecutively
3. Participant could not maintain cadence of lift (2 beats up/2 beats down)
4. Participant demonstrated extremely poor form of lift
The number of repetitions and the duration of the test in seconds for each limb were
recorded.
Assumptions:
1. All participants accurately reported no current (within the last 6 months) shoulder,
cervical or thoracic pathology.
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2. All participants accurately reported no surgery to the shoulder, cervical or
thoracic spines, other than that related to BC treatment.
3. All BCS underwent a mastectomy and/or axillary lymph node dissection and/or
axillary radiation.
4. All participants gave their best effort during measurements of strength, motion,
and muscular endurance.
5. All participants accurately completed self-report questionnaires.
Limitations:
1. No BCS in their fourth decade were recruited.
2. Some participants in the study may have been exposed to physical therapy
intervention in the past, and as a result may have performed differently than those
who had no previous physical therapy.
3. The investigators were not blinded to group during data collection, and the
primary investigator was not blinded to group during data analysis.
4. Primary recruitment of participants was through BC support groups, possibly
biasing this sample toward a group of women with higher levels of support or
resources.
Delimitations
1. The healthy control group consisted of females, ages 30-69, with an ability to read
and write English.
2. The BCS group was limited to females, ages 30-69 who had been diagnosed with
BC and completed surgical treatment at least one year prior to enrollment.
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Surgical treatment must have included at least one of the following: mastectomy,
axillary lymph node dissection, or axillary radiation.
3. All participants were excluded if they had recent (6 month) history of shoulder,
cervical or thoracic spine pathology diagnosed by a physician, or any history of
shoulder, cervical or thoracic surgery.
4. Breast Cancer Survivors were excluded if the surgical treatment of BC was
limited to breast conserving therapy (lumpectomy), or sentinel node biopsy, or
local (tumor bed) radiation.

Copyright © Mary Insana Fisher 2013
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CHAPTER TWO
Current literature related to understanding upper extremity (UE) function and evidence of
UE function among survivors of breast cancer (BCS) is the focus of Chapter Two. The
first section presents evidence supporting UE function as an aspect of, and having an
effect upon, quality of life (QOL). The link between UE function and QOL within the
framework of the International Classification of Functioning, Disability and Health (ICF)
will be established. The second section presents methods to measure UE function,
including subjective and objective measurements. The emphasis is on clinical
measurements rather than laboratory techniques as these will better inform clinical
practice. Lastly, the need for measuring UE function in survivors of breast cancer (BCS)
is presented with evidence outlining the understanding of UE function in long term BCS.
Introduction
Breast cancer (BC) is the most commonly diagnosed non-skin cancer among women,
with 2012 estimates at more than 280,000 new cases of both invasive and in situ cancer.30
With a lifetime risk of 1 in 8 women being diagnosed with BC, greater than 67% of these
cases, will be among women between the ages of 44 and 74.31 Survival rates have
increased 15% in the last 25 years, and currently approach 90%.31 The number of women
diagnosed with and surviving BC has placed prevalence estimates at 2.8 million
women.31 The focus of treatment for BC has broadened from simply focusing on the
cancer itself to ensuring a return to a QOL similar to the pre-cancer diagnosis time point.
The World Health Organization’s ICF7 is a framework to measure and describe
health and disability, and the impact of health conditions on abilities of an individual,
within a context of environmental and social structures. The presentation of health and
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disability within this context of specific domains is the way in which the ICF codifies the
impact of disability on QOL. ICF body structure and function domains comprise
parameters of UE function, including motion, strength, and muscular endurance.7
Impairments in any of one of these three areas can result in limitations in activity and
restrictions in participation, also outlined in the ICF.7 The mobility domain under
activities and participation constructs of the ICF lists carrying, moving, and handling of
objects and the self-care domain includes abilities related to washing, toileting, dressing,
eating and drinking.7 All of these tasks require functional abilities of the UE; the inability
to carry-out tasks within these domains can result in lower reported QOL.
Physical function is one aspect of QOL. Most QOL measures include a physical
functioning subscale within the tool. The physical well-being subscale on the Functional
Assessment of Cancer (FACT-G)32 includes questions related to abilities to meet the
needs of family members. The FACT-B33 has an additional nine items specific to BCS,
one of which focuses on arm swelling, or lymphedema, as a result of BC treatment.
Interference in the ability to use the UE to complete daily tasks can result in lower levels
of QOL whether from the impact of lymphedema, or impairments related to motion,
strength, or muscular endurance.3,34
Given the potential for UE disability following BC treatment and its possible
impact on QOL, it is necessary to identify impairments in physical functioning so they
can be effectively addressed. The purpose of this paper is to: (1) review how UE function
is measured, with an emphasis on measures with clinically feasibility; and, (2) identify
the reported levels of UE function in long term BCS.
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Typical Measures of UE Function
To accurately understand UE functional abilities, a comprehensive assessment of
the different components of function is required. Complete assessment includes
measuring self-reported function, as well as taking objective measures of range of motion
(ROM), strength, and muscular endurance. These measurement tools must be valid and
reliable to gain a thorough clinical view of UE function. The following section focuses
on methods of measurement for each component of UE function, and presents evidence
related to validity and reliability of the measures.
Self-report of UE Function
Clinically, self-report measures are commonly used to describe UE function and
provide the clinician with important information about an individual’s perception of
abilities. Although numerous validated scales have been designed for the UE, those used
in BC research include the Disabilities of the Arm, Shoulder and Hand (DASH),35 the
Penn Shoulder Score,36 and the Constant Murley Shoulder Score.37 Another potentially
useful scale which has not been used in BC research is the Upper Extremity Functional
Index (UEFI).38 Each of these scales includes specific functional activities on which an
individual rates her level of difficulty performing a task. Of these, only the DASH and
the UEFI provide a framework for assessing function based on ICF constructs, therefore
providing an understanding UE function within this contextual framework.
The DASH is a reliable and valid39,40 30 question disability scale which is
commonly reported in BC research studies. The DASH scale is scored 0-100, with
lower scores indicating less disability. Two studies have examined the items on the
DASH in relation to the ICF framework and have found good association to the body
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functions and the activities and participation components of the ICF.41,42 Intraclass
correlation coefficients (ICC) for test-retest reliability range from .77-.98,39,43 and both
construct and convergent validity was established with 3 other shoulder scales: the
American Shoulder and Elbow Surgeons Score, the Simple Shoulder Test, and the
Shoulder Pain and Disability Index.43,44 Normative data for the DASH have been
established for the general United States population using a sample of 1706 participants,
with a mean of 10.1±14.68 reported.45 The effects of age, gender, and type of
employment on DASH scores were examined in a study of 716 employed adults in
Germany, a country with similar a socioeconomic makeup to the United States.46 DASH
scores increased with age, were higher among women than men (14.3±14.9 and
11.6±15.8, respectively), and among manual laborers as compared to non-manual
laborers (15.7±17.2 and 937±12.5, respectively).46
The Upper Extremity Functional Index (UEFI) has not been used in published
research to assess self-reported arm function among BCS; however, it was designed with
the current ICF model as a guide.38 This 20 question scale scores specific functional
tasks on level of difficulty, from 0 (i.e. extremely difficult) to 4 (i.e.no difficulty). A
total of 100% indicates full UE function. The UEFI has a test-retest reliability of
ICC=.95, and good convergent validity with the Upper Extremity Functional Score
(r=.82).38 The questions on this scale pertain specifically to the involved extremity,
differing from the DASH which asks about the level of difficulty in completing a task,
regardless of whether the pathological limb is involved in the task.
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Objective Measures UE Function: ROM, Strength, and Muscular Endurance
Objective measures of UE function include range of motion (ROM), strength, and
muscular endurance. Methods to quantify these measures include both laboratory and
clinical methods. Commonly used clinical tests are reviewed, as well as those less
common but which provide objective and accurate measures.
Range of motion in the clinic is frequently measured using several different
methods: goniometry, photography, and inclinometry. Goniometry provides the clinician
with an inexpensive but reliable method to document motion. In a study of 50
participants referred to physical therapy, both intra- and inter-rater reliability were
examined for all shoulder motions.25 In particular, shoulder flexion motion demonstrated
better intra-rater reliability (ICC = .98) than inter-rater reliability between 2 testers (ICC
= .89), although both methods demonstrated good reliability.25 In a smaller study of 8
participants and four raters, the inter-rater reliability of shoulder flexion measured with a
goniometer was lower (ICC=.69), with a standard error of measurement of 25°.26 This
lower reported ICC value suggests that reliability between more than 2 testers is more
difficult to ensure.
Still photography of a joint presents another option for measuring ROM. By
applying a goniometer on the photo to measure motion, or using specialized software to
measure angles and distances, an exact measurement can be made. In a study examining
the reliability of five methods of measuring shoulder ROM, photography with a
goniometer demonstrated moderate24 inter-rater reliability for shoulder flexion (ICC =
.73).26 When comparing the inter-rater reliability of the goniometer to photographic
measurement, the ICCs are similar, but photography appears to have a slightly higher
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value, suggesting that it may be beneficial to use this method to reduce error in an
environment where multiple clinicians are involved in care.
Inclinometry provides the clinician with another method to measure ROM. The
intra-rater reliability of inclinometry is reportedly better than goniometry with ICC= .90.95.47 However, inter-rater reliability of inclinometry has greater variability as compared
to goniometry with reported ICCs ranging from .28-.90, and differences of measurement
between observers exceeding 10°.47 These findings suggest that inclinometry is best used
by a single examiner rather than in a situation where more than one tester is involved.
Measuring internal rotation ROM with a goniometer can result in lower inter-rater
reliability (ICC = .50-.66)48 because controlling for scapular motion is difficult. In this
situation, internal rotation ROM measures are often performed in a clinically functional
manner by having an individual reach her hand up behind her back. This Hand Behind
Back (HBB) measure is not a true measure of shoulder internal rotation because it
incorporates glenohumeral extension, scapular retraction, downward rotation and elbow
flexion.49,50 However, it does mimic many UE functional motions including dressing,
reaching into back pockets, or reaching behind, and so is a useful clinical tool for
determining whether a limitation may impact functional activities. Furthermore,
concerns over low inter-rater reliability can be addressed by using photography to capture
the motion with one individual measuring the motion.
In a clinical setting, strength is frequently measured using manual muscle testing
(MMT). MMT is a subjective method of grading force of resistance on a 0-5 point scale,
where 0 is no evidence of muscle activity, 3 is full anti-gravity motion without resistance,
and a 5 is full anti-gravity motion with maximal resistance.51 Intra-rater reliability of
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MMT has been reported as high as ICC=.98 for shoulder abduction in a study of 11
participants. 52 Inter-rater reliability is lower; in another study of 11 participants
measuring deltoid strength, the reported kappa was .62.53 An additional but important
limitation of MMT is the inability to provide a specific level of force production which
can be objectively tested and retested over time. Dynamometry can provide a reliable
objective measure of the level of strength where MMT does not.
Dynamometry has traditionally been reserved for laboratory research; however,
the development of hand-held dynamometry (HHD) provides the clinician with a method
to objectively measure strength. Concurrent validity of HHD with isokinetic
dynamometers has been established.54 The reliability of HHD for UE strength testing has
also been established in multiple studies with ICCs ranging from .82-.97.55-57 Some
studies have suggested that the counterforce provided by the examiner can influence
accuracy in measurement. Two studies investigating gender effects in HHD measures
reported that female testers have lower levels of inter-rater reliability than males as
greater stabilization is needed for larger muscle groups.58,59 This problem of an adequate
counterforce can be alleviated by using a consistent stabilization force such as a strap or a
brace.60,61 Normative data and reference values for hand-held dynamometry have been
established and are available for comparisons.62,63
Muscular endurance is an essential component of UE abilities, but because few
clinical measures exist, it is not often tested. A newer test of muscular endurance is the
Functional Impairment Test – Hand and Neck, Shoulder, Arm (FIT-HaNSA).29 This test
examines the ability of an individual to sustain an activity over time in 3 sub-tests of
repetitive UE use. These sub-tests include repetitive lifting at chest height, above head,
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and an overhead manipulation task. The FIT-HaNSA has demonstrated good reliability
(ICC=.79-.97)28,29 and convergent validity with self-report scales (r=.71-.76),28,29 yet no
normative values for this test have been reported.
Another clinical muscular endurance test is the Upper Body Strength and
Endurance Test (UBSE).14 In the UBSE, the participant completes a combination upright
row/shoulder press motion repeatedly as resistance is incrementally increased. The test is
discontinued when the participant can no longer perform the motion correctly, keep a
specific pace, or stops. The psychometric properties of the UBSE have not been
investigated, but this test has been used to examine muscular strength and endurance in a
population of BC survivors.14,15
Recommended Clinical Measures of UE Function
Using valid and reliable tools to measure UE function is important to accurately
assess functional abilities. Those self-report measures of UE function that meet these
criteria include the Penn Shoulder Score (PSS),64 the Constant Murley Shoulder Score
(CSS),65 and the Disabilities of the Arm, Shoulder, Hand (DASH).39,43,44 Although any
of these measures could be used, the DASH has been validated in multiple
populations39,40,43,46 and may be a more versatile tool for clinical use. Reliable and
objective clinical measures include goniometry, including photography, or inclinometry
for ROM, and hand held dynamometry for objectifying strength. Muscular endurance
should be a component of clinical assessment of UE function, yet few valid and reliable
tools are available to the clinician. The FIT-HaNSA is one such tool which could be
incorporated into evaluation. By using a combination of measures, the clinician gains a
clear understanding of UE functional abilities.
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UE Function Among Breast Cancer Survivors
Treating BC can involve extensive surgery to the anterior chest and axillary regions,
which may impact UE function. Women who undergo mastectomies and axillary lymph
node dissection have higher levels of UE morbidities than women who undergo breast
conserving surgery and sentinel node biopsies.6,10,11,66,67 Axillary radiation treatment can
result in further declines of UE function.68,69 This section will review the literature
related to the extent of UE disability and recovery of functional abilities in within and
after the first year of treatment.
UE Function 0-12 months following BC Treatment
Many women treated for BC report that they do not recover to their pre-diagnosis
level of UE function within the first year after treatment. In a study of 188 BCS 6 months
after treatment, 25.6% report Disabilities of the Arm, Shoulder and Hand (DASH) scores
of greater than 20.17 In another study, significantly higher DASH scores were recorded
by 24 BCS less than one year from treatment compared to matched controls.9 Other
studies using non-standardized self-report questionnaires confirm the loss of UE function
for this population.10,70-72 These self-reports of UE functional loss may be the result of
impairment in the components of UE function, including ROM, strength, and muscular
endurance, which occur after BC treatment.
Joint ranges of motion and muscle strength levels have been examined in BCS
following surgical and adjuvant treatment. Diminished motion11,14,20 and strength8,14,16
of the involved extremity have been documented in the first year after BC treatment.
Deficits of up to 10% of flexion motion and 20% of elevation strength are reported when
compared to the contralateral limb.8,14 When examining deficits compared to age
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matched controls, limited data exist. In a comparison of 24 BCS within 6 months of
treatment to matched controls, shoulder flexibility deficits ranged from 7-12%, and
strength deficits reported were up to 27%.9 It is necessary to compare the ROM and
strength of BCS more than one year following treatment to a population of healthy
controls to determine if problems persist beyond the healing stage in the first year.
One study has examined muscular endurance of the involved UE compared to the
contralateral limb in BCS within 12 months of diagnosis. Another study examining
endurance used the Upper Body Strength and Endurance test (UBSE) to record the
weight of the last successfully completed stage in a progressive resistance lifting task.14
In contrast to the shoulder press task, the involved limb in the UBSE study showed a 20%
deficit in muscular endurance compared to the non-involved limb among BCS 6 months
following surgical treatment.14 In the shoulder press task, the use of 90% of 1RM may
bias fast twitch fibers and therefore might not accurately reflect muscular endurance. The
UBSE measures the maximum weight lifted over time, rather than noting duration of
activity, which is the accepted unit of measure for endurance. These inconsistencies in
results do not provide a clear understanding of muscular endurance among BCS.
Impairments in ROM, strength, and muscular endurance in BCS in the short term
have been documented. These impairments likely have an effect on overall UE function
as self-report functional scores indicate. The limitation of these data show deficits
compared to the contralateral limb or to a healthy population in the short term only.
These deficits may not be long term, but rather due to the necessary healing time required
following treatment. Methodological considerations, inconsistencies in results, and the
lack of comparison of BCS to a healthy population provide rationale for further
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investigation of muscular endurance among this population. For a portion of BCS,
motion, strength, and muscular endurance impairments may persist long term, resulting in
compromised UE function past the first year following BC treatment.
UE Function 12 months or More after BC Treatment
The prevalence of UE limitations more than one year after treatment has been
estimated to be 5-60%.17,73 The incidence of UE limitations is estimated from 10-64% in
a population of BCS 12 months or more from treatment.74 The complaints reported by
BCS include pain, lymphedema, and UE functional decline.
Self-report of function assessment among long term BCS reveals a continued
perception that the involved UE is functionally impaired. In a 2 year follow-up of 181
BCS, self-reported function remained impaired as measured by the Shoulder Disability
Questionnaire.12 Self-report of function using the DASH also indicates a continued
perception of functional limitations among long term BCS. One study documented
moderate disability utilizing DASH scores in participants 2-67 months following
treatment, with a mean score of 32.18 Others have documented that over 25% of BCS 6
years after treatment report DASH scores greater than 20.17 Comparisons of self-report
of function between BCS more than 1 year from diagnosis and treatment and a healthy
population have not been reported in the literature. Taken together the studies suggest
that BCS perceive that treatment for BC results in continued UE functional disability
beyond the first year after treatment.
Deficits in motion, strength and muscular endurance of the UE have been
documented more than 5 years following treatment for BC, although the prevalence of
deficits declines from the short term.6,10,12,17,20 Range of motion deficits persisted in more
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than 34% of BCS 5 years after diagnosis,20 with the amount of loss exceeding 25° flexion
and abduction motion in 24-38% of BCS 2-4 years after surgery.12,75 Strength deficits are
often self-reported, but in a study of 131 BCS one year following BC surgery, an 8% loss
in shoulder abduction strength measured by hand-held dynamometry was documented
compared to pre-operative status,10 and in another study of 75 women with a mean time
since surgery of 15 months, strength losses ranged from 7-18% for shoulder elevation
measures.8
In examining the literature related to muscular endurance among long term BCS,
less is known. One study examined an endurance using a test of completing a shoulder
press task at 90% of 1 repetition maximum (1RM) until failure. The number of
repetitions completed by each limb was compared, and no statistical differences between
the involved and non-involved sides were reported.16

Another study conducted at 18

months following BC surgery examined upper body strength and endurance, documented
that 40% of survivors continued to demonstrate deficits comparing involved to noninvolved limbs.15 Whether differences between limbs existed prior to treatment, or are
less than levels seen in a population of healthy women, cannot be determined. In total,
these losses in motion, strength, and muscular endurance can have an impact on function
in a portion of long term BCS.
Although functional deficits which occur immediately following treatment for BC
appear to persist longer than the normal time required for tissue healing, it has not been
clearly established. The need for a study examining self-reported and objective measures
of UE function among long term BCS in comparison to healthy control is needed to
understand the extent of problems.
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Conclusion
Clinical tools to evaluate UE function include validated self-report scales as well
as objective measures to quantify impairment. The most commonly used self-report UE
functional scale for BCS is the DASH, with good reliability and validity.39,43,44 The
extensive use of the DASH in both the BC population and other pathological populations
provides an opportunity to develop an understanding of the extent of functional impact of
BC treatment. This information can then be used by the clinical community to guide
rehabilitation efforts as well as provide a means of prospective surveillance for potential
dysfunction.
Objective clinical measures of UE function have become more precise and
accurate. The use of inclinometry to measure ROM improves accuracy, while HHD
more clearly identifies strength values through objective measures not available with
MMT. Clinical measures of muscular endurance remain one area in which better
assessment tools must be developed. Although the FIT-HaNSA demonstrates good
psychometric properties, the test is time consuming to apply clinically. The UBSE as a
muscular endurance test lacks psychometric validation at this time. Better clinical tools
to measure muscular endurance will provide the rehabilitation community with improved
methods to identify functional status and take necessary steps to address any deficits.
Using these clinical assessments of UE function is an important aspect of
identifying BCS for whom surgical and adjuvant treatment has resulted in impairments of
UE function. Approximately one-third of BCS have persistent losses in ROM and
strength more than one year after treatment.17 These deficits often impair overall UE
abilities.74 By measuring ROM, strength, and muscular endurance, and combining these
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findings with self-report of function, the clinician can developed a focused rehabilitation
program aimed at a return of function.

Copyright © Mary Insana Fisher 2013

23

CHAPTER THREE
This chapter describes typical upper extremity functional performance among a
population of healthy women ages 30-69. The experimental design, including participant
selection, dependent measures, data collection procedures and analysis, results, and
discussion of findings, are presented here. The data from this study will help establish
how these measures change over the decades, and be used in future comparison to
women treated for breast cancer.
Introduction
Adequate motion, strength, and muscular endurance of the upper extremity (UE)
are required to complete functional tasks. These parameters of UE function are detailed
in the International Classification of Functioning, Disability, and Health (ICF) within the
body function domain and are important to understand health within a context of
function.7 Successful performance of activities of daily living has been shown to
correlate with range motion of the shoulder76,77 and is dependent upon adequate strength.
Sustaining functional activity over a period of time requires muscular endurance. The
level of UE functional ability is typically measured with self-report and through objective
measures of motion, strength, and muscular endurance. Following injury or pathology,
an understanding of typical levels of self-reported function and objective measures of
range of motion (ROM), strength, and muscular endurance is needed to be able to
clinically address deficits in any of these areas with the goal of full return to function.
Typical values of UE functional self-report, ROM, strength, and muscular
endurance throughout the adult lifespan have not been consistently documented in the
literature, and when such reports are available, conflicting information emerges. Self-
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report of function using the Disabilities of the Arm, Shoulder and Hand (DASH) shows a
decline in function with increasing age in a sample of 716 individuals,46 but these
declines are not specific to gender. Declines in motion and strength with increasing age
have been reported by several researchers,62,63,78-82 but a clear picture of the age at which
decline begins and whether it is correlated with changes in function, is lacking. Changes
in muscular endurance with aging have been minimally studied; one study reported that
muscular endurance was greater in an older population cohort than a younger one,83 but
the methodology used, isokinetic measures, is not readily available clinically. A clear
picture of the evolving changes in UE function over time needs to be defined.
Whether and to what extent long term deficits in objective measures of shoulder
motion, strength, and muscular endurance among BCS are different than those seen in
normal aging is not clear. By providing typical values of function throughout the adult
lifespan, comparisons between a pathological population and a healthy cohort can be
made. The primary aim of this study is to collect data to describe UE motion, strength
and muscular endurance in a healthy female population aged 30-69. The primary
hypothesis is that as women age, there will be declines in all areas: ROM, strength, and
muscular endurance. A secondary aim is to examine the effect of dominance on
objective measures of UE function. Specifically, it is expected that the dominant
extremity will have less available motion, and greater strength and muscular endurance
than the non-dominant extremity.
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Methods
Subjects
A sample of convenience of 79 healthy women (age 49± 11years) agreed to participate in
this study. To be included in this study, participants had to be between the ages of 30 and
69, and report no history of breast cancer. Participants were excluded if they had recent
(6 month) history of shoulder, cervical or thoracic spine pathology diagnosed by a
physician, or a history of shoulder, cervical or thoracic surgery. All participants read and
signed an approved consent form prior to starting the study. The consent form was
approved by the Institutional Review Boards of the University of Kentucky, Lexington,
Kentucky, the University of Dayton and Miami Valley Hospital, Dayton, Ohio.
Participants were stratified into decades, 30-39, 40-49, 50-59, 60-69, with 20 participants
per decade except the 60-69 group, which had 19. The 4 groups did not significantly
differ in body mass index (BMI) (p=.18) or activity level measured by the International
Physical Activity Questionnaire (IPAQ) (p=.85).
Procedures
Each participant came one time to the clinical laboratory for data collection.
Measurements were taken by three investigators trained in landmark identification for
ROM measures, use of a hand-held dynamometer for strength assessment, and in
administering the Functional Impairment Test – Hand and Neck, Shoulder, Arm (FITHaNSA). The FIT-HaNSA demonstrates good-excellent reliability,24 and ranges from
.89-.99.28,29
Participants completed all self-report forms prior to other components of the
testing. Demographic variables of age and arm dominance were recorded, and height in
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meters and weight in kilograms to the nearest tenth were measured and recorded to
calculate BMI.
Dependent Variables
Self-Report Scales
Activity level was measured using the 7-item International Physical Activity
Questionnaire (IPAQ), which has good test-retest reliability (r= .70-.90).84 Quality of life
was measured using the Functional Assessment of Cancer Therapy – Breast (FACT-B),
which has good construct validity (r=.90) and test-retest reliability (ICC=.88).33 This
scale is comprised of 27 core questions making up the FACT-G (General cancer quality
of life scale), plus 9 additional items specific to breast cancer. Scores range from 0 to
144; higher values indicate a higher quality of life. Self-reported UE function was
measured using the Upper Extremity Functional Index (UEFI), a 20 item questionnaire
with score ranging from 0 to 100, 100 indicating the highest level of function,38 and the
DASH,35 a 30 item disability scale scored 0 to 100, with lower scores denoting less
disability. Both measures have been found to be reliable and valid tools in the evaluation
of UE function.38-40
Objective Clinical Measures:
Range of Motion: Bilateral active ROM of shoulder flexion, hand behind back
(HBB), and external rotation (ER) were measured by taking a photograph of the
participant completing the motion. ImageJ software (National Institutes of Health,
Washington DC) was employed to calculate measurements. This method of measuring
ROM was chosen because multiple investigators were utilized for data collection, and
initial pilot testing with digital inclinometry produced unacceptable inter-rater reliability
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levels. Inter-rater reliability of landmark identification for ROM was established with
further pilot testing and interclass correlation coefficients (ICC) ranged from .90- .99.
The ICC for intra-rater reliability of digital measurement of ROM with ImageJ was
consistently >.95, with a standard error of measurement of less than 2°.
Landmark identification was completed prior to photographing of the motion. For
shoulder flexion, two dots were placed along the midshaft of the humerus aligned with
the greater tuberosity and lateral epicondyle of the humerus, and two additional dots were
placed along the midline of the thorax.85 Active shoulder flexion was measured by
instructing the participant to elevate her arm as high as possible in forward flexion. To
form the shoulder flexion angle, a line was drawn bisecting the two points demarking the
midshaft of the humerus, and another was drawn bisecting the two points of the
midthorax line; the angle in degrees of the intersection of the two lines was measured.85
(Figure 3.1)
For HBB, a marker was placed at C7, an easily and reliably palpated structure.86
The HBB measurement was taken by having the participant reach her hand as high up the
back as possible while standing; a 10cm reference was in the same plane as the
participant. This reference line is necessary to provide a spatial scale of the image so that
measurement results are in calibrated units, and addresses the issue of perspective.87
Using ImageJ software, the reference distance was measured to set the scale of
measurement, and then the distance in centimeters from the C7 spinous process to the
spinous process in line with the tip of the thumb was recorded; a lower value indicates
greater motion.27
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For ER, a dot was placed at the olecranon process and another at the ulnar styloid
process.85 Active shoulder ER was measured with the participant lying supine with the
shoulder abducted and elbow flexed to 90° with the elbow resting on two towels to
approximate the plane of the scapula. The participant was instructed to externally rotate
her arm as far as possible. The ER angle was formed by a line drawn through the shaft of
the ulna and a line perpendicular to the plinth. (See Figure 3.3) Two trials for each
motion and each extremity were recorded, and the mean of these values was calculated.

Figure 3.1: Flexion ROM

Figure 3.2: Hand Behind Back

Arc of motion generated for illustrative
purposes only by Kinovea.org
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Figure 3.3: External Rotation ROM
Arc of motion generated for illustrative
purposes only by Kinovea.org

Strength: The strength of the shoulder flexors, internal and external rotators was
measured by hand-held dynamometry (Lafayette Manual Muscle Test System, Lafayette
Instruments, Lafayette, IN). An inelastic 2” wide nylon strap was placed around the
participant’s wrist for each motion to provide a consistent, immovable resistance for the
hand-held dynamometer. Each participant was instructed to generate force to a maximal
level over 5 seconds in each direction of testing.7,63 Two submaximal practice trials
were completed prior to testing, followed by 3 trials with 10 seconds rest in between. The
average of the 3 trials was used for later statistical analysis.54 Shoulder flexion was
measured with the participant seated, arm elevated to 90°.51 (Figure 3.4) To measure IR
and ER, the participant’s upper arm was supported on two towels while lying supine with
the arm at 90° of abduction and 90°elbow flexion.51 In pilot testing , the ICCs for interrater reliability for strength measures ranged from .78-.80, and the standard error of
measurement was consistently below 1.2%. (Figures 3.5-3.6) Strength was normalized to
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body weight and is presented as a percentage of body weight (kg of force/body weight in
kg).

Figure 3.4: Flexion Strength

Figure 3.5: Internal Rotation Strength

Figure 3.6: External Rotation Strength
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Muscular Endurance: Upper extremity muscular endurance was measured by using the
FIT-HaNSA sub-tests 2 and 3 following a previously established protocol for
performance and termination of testing.29 (Figures 3.7 and 3.8). The FIT-HaNSA
demonstrates good-excellent test-retest reliability (ICC=.79-.97), and moderate
concurrent validity (r=.71-.76) with self-reported UE functional scales.28,29

Figure 3.7: FIT-HaNSA sub-test 2

Figure 3.8: FIT-HaNSA sub-test 3

Statistical Analysis
Data were analyzed using IBM SPSS Statistics 19 (New York, NY). Descriptive
statistics were calculated for all dependent variables. An independent samples t-test was
used to analyze BMI. Mann Whitney U was used to examine activity level (IPAQ), and
self-reported QOL (FACT-B) and function (DASH and UEFI), as these values were not
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normally distributed. A repeated measures analysis of variance (ANOVA) with one
within factor (limb) and one between factor (group) was used to analyze all measures of
motion, strength, and muscular endurance with the exception of the FIT-HaNSA sub-test
3 as this is a bilateral test. There were 2 levels of limb (dominant, non-dominant) and 4
levels of decades (30-39, 40-49, 50-59, 60-69). Significance was set at p ≤.05. If a
significant difference was found, a Tukey’s post hoc analysis was performed to identify
differences with significance set at p≤.05. The FIT-HaNSA sub-test 3 was analyzed with
ANOVA, and Tukey’s post hoc testing was performed if the ANOVA was significant at
p≤.05.
Results
Descriptive analyses with means and standard deviations of all variables are
found in Tables 1-4. The three self-report scales (FACT-B, DASH, UEFI) were not
different between the 4 age groups (p value ranges .16-.59). (Table 3.1) There was no
significant interaction between group by dominance for any measure of motion, strength,
or endurance. Age was found to have a significant main effect on flexion ROM (p=.01).
Tukey’s post hoc analysis identified that 60 year olds (148° ± 8) have less flexion motion
than 30 year olds (159° ± 10) across sides (p=.01). For all other objective measures of
ROM, strength, and muscular endurance, no significant differences were found between
ages (p value ranges .07-.95).
When examining the influence of limb dominance on ROM, there was
significantly less motion for the HBB motion on the dominant side (16.4cm±4.3)
compared to the non-dominant side (13.2cm±4.2) (p<.001); no other differences were
observed for flexion or external rotation (Table 3.2). The dominant limb (9.6%±3.1) was
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stronger than the non-dominant limb (9.0%±3.1) only in flexion (p=.001); no other
differences were found for measures of strength (Table 3.3). The dominant limb
(271sec±54) was observed to have greater endurance than the non-dominant limb
(266sec±63) while performing the FIT-HaNSA sub-test 2 (p=.03) (Table 3.4).
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Table 3.1: Means (standard deviation) for Self-report Measures
Decade
FACT-B Total
DASH
30 (n=20)
124.8 (15)
2.71 (7.2)
40 (n=20)
123.4 (16)
3.03 (5.2)
50 (n=20)
123.0 (24)
2.55 (3.7)
60 (n=19)
127.2 (45)
4.23 ( 4.7)
Total (n=79)
124.6 (27)
3.12 (5.3)

UEFI
98.88 (2.1)
99.12 (1.6)
97.84 (4.0)
97.36 (3.4)
98.32 (2.9)

Abbreviations: FACT-B: Functional Assessment of Cancer Therapy – Breast; DASH: Disabilities of the
Arm, Shoulder and Hand; UEFI: Upper Extremity Functional Index

Table 3.2: Means (standard deviation) Active Range of Motion
Flexion
Hand Behind Back
Decade
30 (n=20)
40 (n=20)
50 (n=20)
60 (n=19)
Total (n=79)

Dominant

159 (10°)
154 (9°)
155 (9°)
148 (8°)
154 (8°)

Non-dominant

Dominant
Non-dominant
14.5 (3.3cm) 13 (3.5 cm)

157 (10°)
156 (10°)
154 (8°)
150 (8°)
155 (9°)

18.2 (5.0cm)
15.5 (2.8cm)
17.2 (4.9cm)
16.4 (4.3cm)

13.1 (5.3 cm)
13.1 (3.2 cm)
13.7 (4.6 cm)
13.2 (4.2 cm)

External Rotation
Dominant

93 (10°)
95 (11°)
93 (8°)
97 (9°)
95 (10°)

Nondominant

93 (11°)
95 (7°)
92 (6°)
95 (8°)
94 (8°)

Table 3.3: Means (standard deviation) Strength (% of body weight)
Flexion
Internal Rotation
External Rotation
Decade
40 (n=20)
50 (n=20)
60 (n=19)
Total (n=79)

Dominant

10.4 (3)
9.3 (3)
8.2 (3)
9.6 (3.1)

Non-dominant

9.8 (3)
8.3 (3)
8.1 (3)
9.0 (3.1)

Dominant

16.0 (.5)
13.9 (.4)
13.1 (.4)
14.5 (4.4)

Non-dominant

15.2 (.4)
13.8 (.4)
13.5 (.5)
14.2 (4.3)

Table 3.4: Means (standard deviation) Endurance (seconds)
Decade
30 (n=20)

FIT-HaNSA sub-test 2
Dominant
Non-dominant

FIT-HaNSA
sub-test 3

275 (48)

276 (47)

286 (32)

40 (n=20)

285 (48)

280 (49)

288 (31)

50 (n=20)

262 (62)

257 (81)

278 (55)

60 (n=19)

262 (60)

250 (70)

277 (48)

Total (n=79)

271(54)

266(63)

282(42)
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Dominant

14.9 (3)
14.3 (5)
13.9 (5)
14.4 (4.4)

Non-dominant

14.6 (4)
14.7 (5)
13.7 (5)
14.5 (4.7)

Discussion
The primary aim of this study was to describe and determine if differences occur with
aging in self-reported measures of QOL and UE function, and ROM, strength, and
muscular endurance among healthy women ages 30-69. The hypothesis that these
measures would decrease with increasing age was not met for 10 of 11 variables. These
findings suggest that in general, the level of ROM, strength, and muscular endurance do
not change in women between the ages of 30 through 69, and future comparisons
between women with UE pathology to a group of healthy controls, age does not need to
be considered. The secondary hypothesis, that the dominant limb would show less
motion, and greater strength and endurance than the non-dominant limb, was met for 3 of
7 measures. Dominance does play a role in some measurements of ROM, strength, and
endurance, and therefore, limb to limb comparisons should not be relied upon to provide
accurate comparisons.
Self-Report Scales
Quality of life as reported using the FACT-B was consistently high in this
population. No studies have reported mean scores on the FACT-B in a healthy
population however, in a study of over 1000 healthy individuals, the mean score on the
FACT-G was 80.88

Calculating the FACT-G scores from this study sample, the range is

87-91, comparable to previously reported research.88 The overall high scores seen in this
sample population suggest that QOL does not diminish with age. It should be noted
however, that the FACT-B is specific to women treated for BC, and many questions on
the scale would not apply to an individual without BC. Although the scale can be scored
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with skipped questions, it is possible that the results cannot truly measure QOL among a
population who has not had an experience with BC.
Self-reported arm function using the DASH and UEFI showed no significant
functional decline across the four decades. Mean DASH scores in this study, ranging
from 2.55 – 4.23, are somewhat lower to those reported in other research.45,46 These
findings indicate that the sample in this study is without UE functional disability. UEFI
scores exceeded 97 for all age groups. No published data are available for UEFI in a
healthy population, but 2 studies in a pathological population report a mean and standard
deviation far lower (43.2±17.738 and 65.2±17.989) which would indicate that the
participants in this study are likely representative of a healthy sample. Overall, the
sample of women in this study presented with little to no perceived level of upper
extremity disability and a high level of self-reported function.
The Impact of Age on ROM, Strength, and Muscular Endurance
Only shoulder flexion ROM decreased with increasing age, while age showed no
effect on all other dependent measures. These findings are consistent with other research
on the impact of age on ROM changes, with no changes noted in a study of 90 women
under the age of 60,81 and a decline in flexion motion noted between 2 groups of women
aged 50-69 and over 70.90 The findings in this study suggest that the decline in shoulder
flexion ROM may occur in latter decades. Furthermore, the mean values for active ROM
for shoulder flexion (148°-159°) in this study are consistent with other studies using
goniometry.78,79 Our use of digital photography and software to measure precise angles
resulted in high reliability and low measurement error, but is essentially the same process
as traditional goniometric measurement.
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A minimum of 120° of shoulder flexion is required to complete UE functional
tasks such as hair care, bathing, feeding, and most reaching tasks, 76,91 and 148° is the
threshold required to reach high shelves.92 All mean flexion values in this study were
148° or greater. These values indicate that in this sample women appear to retain the
flexion motion necessary to complete even higher level UE functional tasks. Trends
toward declining flexion motion over time have been suggested by other
researchers,78,81,90 and these changes may impact function. Younger participants in this
study showed greater flexion values, providing them with approximately 15-20% reserve
capacity in motion should any shoulder pathology result in a decline in flexion motion,
while older participants have less reserve capacity available before ROM loss impacts
function. Awareness of this trend is important to consider when presenting with an UE
pathology.
Although data are not available on typical HBB distance among a healthy
population, the mean value of the HBB measure in this study indicates greater mobility
than is seen in pathological populations;26,49 no study has previously examined change in
HBB with aging. Comparison of the HBB to other studies investigating IR ROM is
difficult as the measures are not identical. Internal rotation measured using HBB is
commonly used clinically and mimics functional tasks such as donning/doffing a bra or
tucking in a shirt. We selected this method to improve reliability of our measure as
stabilizing the scapula for pure glenohumeral internal rotation was found to be difficult
between multiple examiners. It should be understood that measuring the distance from C7
to the tip of the thumb represents more than shoulder internal rotation; it also incorporates
shoulder extension and scapular mobility,49 yet remains a useful functional description of
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shoulder motion, and is considered a more accurate measure than identifying vertebral
level of hand placement.27 As the minimum distance of the HBB measure required to
complete functional tasks has not been established, it is difficult to identify at which point
a lack of motion might interfere with UE function. The clinician, then, should combine
the measurement with functional abilities questions to determine whether a lack of
motion is impacting function.
The mean values of ER ROM (92°-97°) of this study sample are consistent with
other research,78,79 but literature is inconsistent in terms of increases or decreases with
rotation motion over time.79,90 Minimum values of ER motion to complete functional
tasks such as placing items on shelves, hair care, and opening doors require no more than
approximately 60°.91 All participants demonstrated ER in excess of 90°, indicating no
functional loss of ROM is present in this sample. Furthermore, mean values in this study
suggest that healthy women ages 30-69 possess a significant buffer of 30% of ER ROM
should future pathology limit this motion. In this study, no change in ER was seen with
aging, suggesting that everyday UE use is sufficient to retain functional ranges.
Age did not impact any strength measurements of participants in this study. The
mean flexion and rotational strength values in this study were lower by approximately
20-50% than those reported by other researchers using hand-held dynamometry,62,63
however, conflicting results may be attributed to a difference in methodologies. The
dynamometer placement for shoulder flexion in one study was just proximal to the
humeral epicondyles 62 rather than more distally at the ulnar styloid process as in our
study. This change of position shortens the lever arm and subsequently increases force
production. The rotation measures were taken at 45° of abduction 63 rather 90° as in our
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study. Again, a change in the amount of abduction can change force production. No
research has detailed minimum strength measures to complete functional tasks. When
examining our strength levels in light of UE function, since participants in this study
reported minimal disability or functional decline, it can be construed that the strength
measures obtained are adequate to complete most functional tasks.
Muscular endurance does not appear to change across the decades from ages 30 to
69. The mean endurance times for sub-tests 2 and 3 of the FIT-HaNSA in this study are
in agreement with previous literature in a healthy population.28,29 Furthermore, it is
interesting to note that in the current study the mean age is 20 years greater than in these
published studies. This suggests muscular endurance appears to remain stable with
increasing age. As participants in this study reported no significant functional
limitations, the mean values reported here indicate this healthy sample has adequate
endurance to complete functional tasks.
The Impact of Dominance on Motion, Strength, and Muscular Endurance
The results of this study show that dominance impacts certain motions, but not all.
The HBB motion was found to be significantly less for the dominant arm, and although
some researchers did not find that dominance had an effect on HBB ROM,79,81 others
have substantiated this difference.78,90,93 Diminished IR ROM on the dominant limb has
been documented in literature related to throwing athletes, and this decline has been
attributed to an increase in humeral retroversion, as well as muscular changes resulting
from the demands on the limb.94 In gathering data on the participants in this study, we
only examined current activity level but did not investigate what specific activities in
which these individuals participated presently or in the past. It is possible that the
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decreased HBB measure on the dominant limb may be related to similar physiological
changes seen in throwing athletes based on activity participation. Whether less HBB
motion on the dominant extremity impacts functional tasks is unclear, however since the
self-report of function scores do not indicate any functional deficit, it could be concluded
that the difference is not clinically important.
Dominance appears to affect strength only for the shoulder flexion measurement
in this study. Other researchers have found that dominance had an effect on both flexion
and rotation strength measures,62,82 while the rotation strength measurements in this study
were similar for both dominant and non-dominant limbs. The flexion strength difference
between limbs in this study is not likely clinically significant as the difference is small
(less than 1% of body weight), and self-report scores do not indicate functional deficits.
Muscular endurance does appear to be affected by dominance. For sub-test 2 of
the FIT-HaNSA, participants had significantly greater endurance on the dominant limb
when compared to the non-dominant limb. To our knowledge, this is the first study
examining the impact of dominance on muscular endurance using the FIT-HaNSA in a
healthy population. This dominance effect conflicts with a study of 20 healthy
participants (male and female) who completed a unique test of muscular endurance on 2
separate occasions.95 On the first test session, the non-dominant limb showed greater
endurance, but on the second session, the durations were equal.95 This retest increase in
endurance was attributed to effects of motor learning.95 Further investigation of muscular
endurance of the UE will need to occur to determine the impact of dominance, but the
findings of this study suggest that dominance must be considered when measuring
muscular endurance of the upper extremities.
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Limitations and Future Research
This current study had several limitations. By choosing to measure IR ROM by
using the HBB measure, we were not measuring pure IR motion, limiting our ability to
compare our findings with other research, and our ability to determine whether
differences were due to any particular motion. Limited information is available on
typical values of HBB in a healthy population, and we lacked data on specific physical
activities in which participants engaged, limiting our ability to determine whether sport or
activity impacted the HBB measure. The HBB measure, however, remains a functional
measure of ability to reach behind the back and is a clinically relevant concern of most
patients with upper extremity disorders.
The use of hand-held dynamometry quantifies muscular strength and can be
performed easily in the clinic, where manual muscle testing remains subjective.
However, the method to stabilize the hand-held dynamometer is important for accurate
measurement.58,59 We attempted to minimize this issue by using a resistant nylon strap
and the clinician as the stabilizing force however, it is possible that inaccurate measures
were taken resulting in the lack of differences between limbs observed.
Future research should focus on reliable, valid, and clinically feasible methods to
measure UE strength with a hand-held dynamometer. Muscular endurance measures
across ages needs to be established, and differences based on dominance need to be
further explored. Furthermore, the link between objective clinical measures and selfreport of function needs to be identified.
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Conclusion
The findings in this study show that only flexion motion declines with aging,
however, does appear to remain within functional ranges. The decline in the 60+ age
range, however, leaves less reserve capacity for loss of motion due to pathology.
Strength and muscular endurance appear to remain stable throughout the ages assessed in
this study. Dominance plays a role in motion, strength, and muscular endurance. These
limb-to-limb differences need to be considered in clinical evaluations. It is often a
convenient comparison to measure to the contralateral side using the assumption that
limbs are symmetrical, but it appears that in an otherwise healthy population there are
some measures that are asymmetrical. Comparisons to typical values or normative data
may provide a more accurate assessment of these objective measures of shoulder function
than limb to limb comparisons typically done in the clinic.
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CHAPTER FOUR
The focus of this chapter is the comparison of upper extremity function between
survivors of breast cancer (BCS) and a population of healthy women, using in part data
derived from the first study (Chapter 3). Additionally, the differences between the
involved and non-involved limbs of BCS, considering whether the involved limb is the
dominant limb, will be investigated. Typical levels of self-reported quality of life (QOL)
and arm function, and values of shoulder range of motion (ROM), strength, and muscular
endurance of BCS will be presented. Differences between BCS and controls, and
involved/non-involved limbs are discussed, and the need for more responsive measures of
muscular endurance are presented.
Introduction
Functional performance of the upper extremity (UE) includes adequate levels of
ROM, strength, and muscular endurance, defined both through the International
Classification of Functioning, Disability, and Health (ICF) and the ICF Core Set for
breast cancer (BC).7,13 Persistent complaints of UE functional deficits in long term BCS
have been documented,6,70,73,96-98 but the extent of these deficits and whether they can be
attributed to BC treatment or normal aging has not been adequately examined.
Specifically, 21% of long term BCS report a decline in UE function measured on the
Disabilities of the Arm, Shoulder and Hand (DASH) scale up to 6 years following
diagnosis.17 A 10% decline in ROM has been reported more than 5 years following
treatment for BC.18 Strength declines of 10-15% are reported 1-5 years after
treatment.8,18 These studies have examined UE function in relation to self-report and the
contralateral limb, but have not made a direct comparison to a group of healthy women.
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These deficits may actually be a result of changes seen with normal aging. It is important
for direct comparison of measures of UE function between BCS and healthy women to
determine whether existing deficits are due to BC treatment or normal aging.
Muscular endurance, the ability to sustain an activity over time and a necessary
component of UE function,7 has been minimally examined in the BC population. In a
study using 90% of 1 repetition maximum (1RM) weight in a repetition to failure
activity, no significant differences between involved and non-involved limbs were
found,16 however, using 90% of 1RM may bias strength rather than endurance muscle
fibers. A unique test of upper body strength and endurance (UBSE)14 was used in 2
studies. At 6 months, a 20% deficit in the involved limb of BCS was documented, which
declined to 10% but persisted at 18 months.14,15 These inconsistent findings and limited
data on muscular endurance in long term BCS warrants the need for further investigation
into UE muscular endurance as a component of UE function.
Subjective self-reported function and objective ROM, strength, and muscular
endurance measures of BCS in comparison to a healthy cohort need to be examined in
order to identify whether the potential deficits are due to BC interventions or to the
normal aging process. The purpose of this study is to determine the extent of UE
functional deficits in BCS compared to a population of healthy controls. We hypothesize
that BCS will have lower levels of self-reported QOL and UE function, and ROM,
strength, and muscular endurance compared to women without a history of BC. A
secondary aim is to examine differences between the involved and non-involved limb of
BCS who are at least 12 months post treatment, also considering dominance. We
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hypothesize that the involved limb will have less motion, strength and endurance
compared to the non-involved limb in BCS.
Methods
Subjects: A sample of convenience of 50 BCS agreed to participate in this study. To be
included in this study, participants had to be between the ages of 30 and 69, and have
received at least one of the following BC treatments: mastectomy, axillary lymph node
dissection (ALND), axillary radiation. All treatments had to be completed 12 months or
more from the date of testing. Participants were excluded if they had recent (6 month)
history of shoulder, cervical or thoracic spine pathology diagnosed by a physician, or a
history of shoulder, cervical or thoracic surgery. All participants read and signed an
approved consent form prior to starting the study. The consent form was approved by the
Institutional Review Boards of the University of Kentucky, Lexington, Kentucky, the
University of Dayton and Miami Valley Hospital, Dayton, Ohio. One participant with
breast cancer was excluded after screening revealed she had undergone rotator cuff
surgery on her involved side prior to the cancer diagnosis. Two other BCS were
excluded after clarification that the radiation received was local to the tumor site and not
the axilla. Additionally, 5 BCS had been diagnosed with bilateral BC, and were excluded
as limb to limb comparisons could not be made. Forty-two BCS are included in the final
analyses. Data from the initial study describing typical values of UE function among
women without breast cancer (Chapter 3) were used for comparison. Women who had
not had breast cancer ages 30-39 were excluded from final analysis for comparison as no
breast cancer survivors in the same age range were recruited with a resulting 59 women
without breast cancer.
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Procedures: Each participant came one time to the clinical laboratory for data collection.
Measurements were taken by three investigators trained in landmark identification for
ROM measures, use of a hand-held dynamometer for strength assessment, and in
administering the Functional Impairment Test – Hand and Neck, Shoulder, Arm (FITHaNSA). The FIT-HaNSA demonstrates good-excellent reliability,24 and ranges from
.89-.99.28,29
Participants completed all self-report forms prior to other components of the
testing. Demographic variables of age and arm dominance were recorded, and height in
meters and weight in kilograms to the nearest tenth were measured and recorded to
determine BMI.
Dependent Variables
Self-Report Scales
Activity level was measured the 7-item International Physical Activity Questionnaire
(IPAQ), which has good test-retest reliability (Spearman correlation coefficients .70.90).84 Quality of life was measured using the Functional Assessment of Cancer Therapy
– Breast (FACT-B), which has good construct validity (r=.90) and test-retest reliability
(ICC=.88).33 This scale is comprised of 27 questions making up the FACT-G (General
cancer quality of life scale) plus 9 additional items specific to breast cancer for a score of
ranging from 0 to144; higher values indicate a higher quality of life. Self-report of UE
function was measured by the Upper Extremity Functional Index (UEFI), a 20 item
questionnaire with score ranging from 0 to 100, 100 indicating the highest level of
function,38 and the DASH, a 30 item disability scale scored 0 to 100, with lower scores
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denoting less disability. Both measures have been found to be reliable and valid tools in
the evaluation of UE function.38-40
Objective Clinical Measures:
Range of Motion: Bilateral active ROM of shoulder flexion, hand behind back
(HBB), and external rotation (ER) were measured by taking a photograph of the
participant completing the motion. ImageJ software (National Institutes of Health,
Washington DC) was employed to calculate measurements. This method of measuring
ROM was chosen because multiple investigators were utilized for data collection, and
initial pilot testing with digital inclinometry produced unacceptable inter-rater reliability
levels. Inter-rater reliability of landmark identification for ROM was established with
further pilot testing and interclass correlation coefficients (ICC) ranged from .90- .99.
The ICC for intra-rater reliability of digital measurement of ROM with ImageJ was
consistently >.95, with a standard error of measurement of less than 2°.
Landmark identification was completed prior to photographing of the motion. For
shoulder flexion, two dots were placed along the midshaft of the humerus aligned with
the greater tuberosity and lateral epicondyle of the humerus, and two additional dots were
placed along the midline of the thorax.85 Active shoulder flexion was measured by
instructing the participant to elevate her arm as high as possible in forward flexion. To
form the shoulder flexion angle, a line was drawn bisecting the two points demarking the
midshaft of the humerus, and another was drawn bisecting the two points of the
midthorax line; the angle in degrees of the intersection of the two lines was measured.85
For HBB, a marker was placed at C7, an easily and reliably palpated structure.86
The HBB measurement was taken by having the participant reach her hand as high up the
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back as possible while standing; a 10cm reference was in the same plane as the
participant. This reference line is necessary to provide a spatial scale of the image so that
measurement results are in calibrated units, and addresses the issue of perspective.87
Using ImageJ software, the reference distance was measured to set the scale of
measurement, and then the distance in centimeters from the C7 spinous process to the
spinous process in line with the tip of the thumb was recorded; a lower value indicates
greater motion.27
For ER, a dot was placed at the olecranon process and another at the ulnar styloid
process.85 Active shoulder ER was measured with the participant lying supine with the
shoulder abducted and elbow flexed to 90° with the elbow resting on two towels to
approximate the plane of the scapula. The participant was instructed to externally rotate
her arm as far as possible. The ER angle was formed by a line drawn through the shaft of
the ulna and a line perpendicular to the plinth. Two trials for each motion and each
extremity were recorded, and the mean of these values was calculated.
Strength: The strength of the shoulder flexors, internal and external rotators was
measured by hand-held dynamometry (Lafayette Manual Muscle Test System, Lafayette
Instruments, Lafayette, IN). An inelastic 2” wide nylon strap was placed around the
participant’s wrist for each motion to provide a consistent, immovable resistance for the
hand-held dynamometer. Each participant was instructed to generate force to a maximal
level over 5 seconds in each direction of testing.7,63 Two submaximal practice trials
were completed prior to testing, followed by 3 trials with 10 seconds rest in between. The
average of the 3 trials was used for later statistical analysis.54 Shoulder flexion was
measured with the participant seated, arm elevated to 90°.51 To measure IR and ER, the
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participant’s upper arm was supported on two towels while lying supine with the arm at
90° of abduction and 90°elbow flexion.51 In pilot testing, the ICCs for inter-rater
reliability for strength measures ranged from .78-.80, and the standard error of
measurement was consistently below 1.2%. Strength was normalized to body weight and
is presented as a percentage of body weight (kg of force/body weight in kg).
Muscular Endurance: Upper extremity muscular endurance was measured by
using the FIT-HaNSA sub-tests 2 and 3 following a previously established protocol for
performance and termination of testing.29 The FIT-HaNSA demonstrates good-excellent
test-retest reliability (ICC=.79-.97), and moderate concurrent validity (r=.71-.76) with
self-reported UE functional scales.28,29
Statistical Analysis
Data were analyzed using IBM SPSS Statistics 19 (New York, NY). Descriptive
statistics were calculated for all variables of self-reported QOL and function, ROM,
strength, and muscular endurance for each group. To confirm that the characteristics of
each group were similar, independent samples t-tests were used to analyze age, BMI and
activity level.
Whether the dominant or the non-dominant limb was the involved limb in BCS
had to be considered prior to data analysis. This is based on findings from previous
research in Chapter 3 which show that dominance has an effect on at least one measure in
ROM, strength, unilateral muscular endurance tasks. Therefore, the BCS group was
subdivided into two groups: involved dominant or involved non-dominant. The level of
complexity of comparisons resulted in multiple analyses being conducted. (Figures 4.14.2) Significance for all analyses was set a priori at p≤.05.
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BCS Involved Dominant
BCS Involved Non-dominant
Control

MANOVA

Self-Report
of Function

ANOVA

Quality of Life
FACT-B

ANOVA

Endurance
FIT-HaNSA
Subtest 3

Which Measure
DASH
UEFI

Post hoc Tukey

Post hoc Tukey

Group Determination

• BCS Involved Dominant
Group Determination
• BCS Involved Non-dominant
• Control

Group Determination

• BCS Involved Dominant
• BCS Involved Non-dominant
• Control

BCS = Breast Cancer Survivor
ANOVA = Analysis of variance
MANOVA = Multivariate analysis of variance
ROM = Range of motion
FACT-B = Functional Assessment of Cancer Therapy – Breast
FIT-HaNSA = Functional Impairment Test – Hand and Neck, Shoulder, Arm
DASH = Disabilities of the Arm, Shoulder, Hand
UEFI = Upper Extremity Functional Index
HBB = Hand Behind Back ROM
IR = Internal Rotation Strength
ER = External Rotation

Figure 4.1a: Statistical Analyses for Between Group Comparisons; All 3 Groups

51

BCS Involved Dominant
BCS Involved Non-dominant

Control Dominant
Control Non-dominant

MANOVA

Strength

ROM

ANOVA

ANOVA

Endurance
FIT-HaNSA
Subtest 2

Which Measure

Flexion
HBB/IR

BCS = Breast Cancer Survivor
ANOVA = Analysis of variance
MANOVA = Multivariate analysis of variance
ROM = Range of motion
FACT-B = Functional Assessment of Cancer Therapy – Breast
FIT-HaNSA = Functional Impairment Test – Hand and Neck, Shoulder, Arm
DASH = Disabilities of the Arm, Shoulder, Hand
UEFI = Upper Extremity Functional Index
HBB = Hand Behind Back ROM
IR = Internal Rotation Strength
ER = External Rotation

Figure 4.1b: Statistical Analyses for Between Group Comparisons;
Limb to limb Comparisons
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BCS Involved Dominant
BCS Involved Non-dominant

BCS Non-involved Non-dominant
BCS Non-Involved Dominant

MANOVA

Strength

ROM

ANOVA

ANOVA

Endurance
FIT-HaNSA
Subtest 2

Which Measure

Flexion
HBB/IR

Figure 4.2: Comparison of Involved to Non-involved Limbs of BCS
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Comparison between the BCS and Control Group
We first analyzed the FACT-B scores and sub-test 3 of the FIT-HaNSA, (a
bilateral task) using two separate ANOVAs, with three groups: BCS involved dominant,
BCS involved non-dominant, and control group. If significance was found, post hoc
testing with Tukey’s was used to determine for which group significance was found.
Direct comparisons of the involved limb of BCS to the respective limb of the
control group were necessary for the FIT-HaNSA sub-test 2, a unilateral endurance task.
Two separate ANOVAs were performed comparing BCS involved dominant limb to the
dominant limb of the control group, and BCS involved non-dominant limb to the nondominant limb of the control group. With only 2 groups being compared, no post hoc
testing was necessary.
To compare differences in self-report of function between the BCS and control
group, a MANOVA was used because the comparison involved two related measures
(UEFI and DASH), and three groups (BCS involved dominant, BCS involved nondominant, and control). If significance was found, a subsequent ANOVA was performed
to determine which measure was involved. Significant differences on the ANOVA were
analyzed post hoc with Tukey’s to determine for which group significant differences
existed.
The dependent variables ROM and strength each had 3 measures (flexion,
HBB/IR, ER) on 2 limbs (dominant and non-dominant); therefore results could be
related. Consequently, the MANOVA model was used assessing these potential
relationships. Four separate MANOVAs were used to compare the involved limb of BCS
to the respective limb of the control group: ROM dominant, ROM non-dominant,
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strength dominant, and strength non-dominant. Direct comparisons were made between
the involved dominant limb of BCS to the dominant limb of control group, and the
involved non-dominant limb of the BCS to the non-dominant limb of the control group.
In the presence of a significant difference in these variables, ANOVAs were carried out
to determine for which specific variable differences existed. As only 2 groups were
involved, either BCS involved dominant and the dominant limb of controls, or BCS
involved non-dominant and the non-dominant limb of controls, no post hoc testing was
needed.
Figure 4.1 details the analyses performed comparing BCS to the control group.
BCS Involved to Non-involved Comparison
Because dominance may impact some dependent measures, the BCS group
subdivisions were maintained: involved dominant and involved non-dominant. To
compare involved and non-involved limb in BCS, the change score of the involved limb
minus the non-involved limb was calculated for all measures of ROM, strength, and
muscular endurance (FIT-HaNSA sub-test 2, only). The affected limb, dominant or nondominant, was considered as a fixed factor in comparisons. Significance was set a priori
at p≤.05 for all analyses. Figure 4.2 details these analyses.
The ANOVA model was used to compare the change score on sub-test 2 of the
FIT-HaNSA. Two separate MANOVAs were used to compare ROM and strength
variables. In the presence of a significant difference in these variables, ANOVAs were
carried out to determine for which specific variable differences existed. No post hoc
testing was necessary for 2 group comparisons.
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Results
Participant demographics of age (p=.50), body mass index (p=.53) and activity levels
were similar. (Table 4.1) Among BCS, the mean duration since surgical treatment was 69
months (range 12-241); 31 underwent a mastectomy, 20 underwent ALND, and 13 had
axillary radiation. Of these, 11 BCS had both a mastectomy and ALND, and 6 underwent
all three procedures.
Comparison Between the BCS and Control Group
Quality of life measured by the FACT-B was statistically significantly lower
among BCS compared to the control group (p=.040). (Table 4.2) Post hoc testing
showed that this was the case for women whose BC was on the non-dominant limb
(p=.050), with mean values for BCS (108±17.4) lower compared to the control group
(124.7±30.7).
The MANOVA was significant for self-report functional measures (p<.001), with
the subsequent ANOVA showing both UEFI and the DASH were significant at p<.001.
Post hoc testing revealed BCS report lower levels of UE function and higher levels of UE
disability than the control group, regardless of whether the involved limb was on the
dominant or non-dominant side. (Table 4.2)
For ROM measures comparing the involved limb of BCS to the respective limb of
controls, MANOVAs were significant for both dominant and non-dominant ROM. For
dominant limb ROM, both flexion (p=.01) and ER (p=.03) ROM were less in the BCS
group than the control group. When the non-dominant limb was the involved limb, all 3
ROM measures, flexion (p=.001), HBB (p=.01), and ER (p=.01) ROM were less in the
BCS group compared to the control group. (Table 4.3)
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Strength measures were significantly lower in BCS only when the non-dominant
limb was the involved limb. Non-dominant IR (p=.004) and ER (p=.004) strength were
less among BCS when compared to the control group. (Table 4.4)
Muscular endurance measured by the FIT-HaNSA was not different between BCS
and the control group. The mean of control group and BCS for sub-test 2 on the dominant
limb was 270±57sec and 248±84sec, respectively (p=.18), and for the non-dominant
limb, the mean for the control group was 263±68sec, and BCS 244±70sec (p=.30). The
mean of the control group for sub-test 3 was 281±45sec, and for BCS it was 271±61sec
(p=.61).
BCS Involved to Non-involved Comparison
MANOVA results of the involved to non-involved limb were statistically
significant different for ROM only (p<.001); all other dependent variables were not
significantly different for strength measures (p=.35), and sub-test 2 on the FIT-HaNSA
(p=.07). Subsequent ANOVA testing on ROM revealed that HBB and ER were
significantly different between the involved and non-involved sides. In examining the
specific direction of differences, these findings indicate that the dominant limb had on
average 3 cm less HBB motion than the non-dominant limb, regardless of BC
involvement (p<.01). Similar results were observed for ER ROM (p=.03). In those
women who had BC on their dominant side, ER was 4° greater than on the non-involved
non-dominant side. Among BCS with BC on the involved non-dominant side, dominant
ER was 5° greater on the dominant non-involved side. Dominant ER ROM was greater
regardless of which side BC occurred.
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Table 4.1: Baseline Characteristics (mean (SD))
Age, years
54 (8)
56 (8)

Control (n=59)
BCS (n=42)

BMI
26.8 (5.4)
27.9 (6.3)

IPAQ (mets)
3190 (2926)
3260 (4056)

Abbreviations: BMI = Body Mass Index; IPAQ = International Physical Activity Questionnaire

Table 4.2: Self-Report Scores (mean (SD))
Control (n=59)
BCS Involved Dominant (n=23)
BCS Involved Non Dominant (n=19)

FACT-B
124.7 (30.7)
114 (16.2)
108 (17.4)

UEFI
98.1 (3.2)
91.2 (9.7)
89.9 (11.7)

DASH
3.3 (4.6)
11.5 (11.3)
10.3 (13.4)

Abbreviations: FACT-B = Functional Assessment of Cancer Therapy, Breast; UEFI = Upper
Extremity Functional Index; DASH = Disabilities of the Arm, Shoulder, Hand

Table 4.3: Range of Motion (mean (SD))
Control
BCS

Dominant

Flexion
Non-dominant

152°(9)
146°(13)

153°(9)
142°(18)

Hand Behind Back
Dominant
Non-dominant

17cm (4.5)
18cm (5.6)

13.5cm (4)
16.9cm (6.4)

External Rotation
Dominant
Non-dominant

95°(9)
89°(11)

94°(7)
87°(14)

Control n = 59, BCS Involved Dominant n = 23, BCS Involved Non-dominant n = 19.
For BCS, all motions are on the involved limb only.

Table 4.4: Strength (% Body Weight) (mean (SD))
Control
BCS

Dominant

9.3 (3)
8.3 (2.6)

Flexion
Non-dominant

8.7 (3)
7.6 (2.7)

Internal Rotation
Dominant
Non-dominant

14.3 (4.5)
12.9 (4.5)

14.2 (4.2)
11 (3.5)

External Rotation
Dominant
Non-dominant

14.3 (4.2)
14.6 (5.8)

Control n = 59, BCS Involved Dominant n = 23, BCS Involved Non-dominant n = 19.
For BCS, all strength measures are on the involved limb only.
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14.3 (4.4)
10.8 (4.7)

Discussion
This study compared self-reported QOL and UE function levels, and objective
measures of function limited to shoulder ROM, strength, and muscular endurance in BCS
and healthy controls. This study was unique in that it directly compared BCS to a group
of healthy women, considering limb dominance. These comparisons have been
minimally investigated among long term BCS. We hypothesized that BCS would have
lower levels of self-reported QOL and UE function, and objective measures of motion,
strength, and muscular endurance than a sample of women without BC, which was true
for most but not all variables. Women treated for BC report lower QOL levels, lower UE
function and higher disability, and demonstrate less overall UE ROM, and less IR and ER
strength, than a sample of women without breast cancer. We expected that long term
BCS would have lower objective measures of ROM, strength, and muscular endurance on
the involved limb compared to the non-involved limb but this was not found to be true in
this sample. Range of motion results indicated differences were due to arm dominance,
rather than the impact of BC treatments.
Comparison Between the BCS and Control Groups
Among women whose BC occurred on the non-dominant limb, statistically lower
values of QOL were reported compared to the control group, suggesting that this
subgroup of BCS may have more difficulty returning to a level of QOL similar to healthy
counterparts. Only one study examined the impact of the whether the cancer occurred on
the dominant or non-dominant side on QOL, and in a study of 59 BCS with lymphedema,
QOL was not associated with side of cancer.99 The sample population in this current
study did not have lymphedema, perhaps accounting for a difference in findings. Yet,
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when examining the levels of QOL and objective measures of function among BCS,
those with cancer on the non-dominant limb not only have lower QOL levels, but also
consistently demonstrate statistically significantly lower ROM and strength than a sample
of healthy women. These findings may indicate that in this sub-population of BCS,
return of function and QOL may not reach the same levels as when cancer occurs on the
dominant limb, perhaps because the non-dominant limb is not used as frequently. The
effects of dominance on QOL need further investigation.
Self-report of UE function on both the DASH and UEFI were statistically
significantly lower among BCS compared to levels reported by a healthy sample,
however the values are not clinically significant. Although the mean values of the DASH
for BCS in this study were similar to a study of 53 BCS who underwent a mastectomy at
least 12 months prior to measurement (range: 10.12 ±9.39 - 12.97 ±11.6),100 they are
lower compared to reports of BCS 6 months after treatment whose mean DASH score
was 19.4 ±17,9 suggesting that there is a perceived return of function occurring over time.
In evaluating our results in comparison to those of a general population, BCS report
similar levels of function. The mean DASH score of a general population sample of 1706
adults was 10.1±14.7,45 and among 327 healthy women age 18-65 was 14.3±14.9.46 The
mean score on the DASH among BCS 6 years after treatment in this study are
approximating these cited values, and indicate that recovery of function to normal ranges
can occur with adequate time.
Nearly all ROM measures in BCS were impaired by 5-10% compared to a healthy
sample even at 6 years post-treatment. Only the HBB measure on the dominant involved
side was not significantly diminished, and even in a healthy population, there appears to
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be limited IR motion on the dominant side compared to the non-dominant side.94 The
mean shoulder flexion motion among BCS in this study is 11-15° less than that reported
among BCS within the first 6 months after treatment,9 suggesting that shoulder flexion
ROM loss may continue past one year. Although none of the motions declined to what is
generally accepted as clinically significant level, a minimum range of 148° of shoulder
flexion is necessary for reaching a high shelf.92 A secondary analysis of BCS with
motion less than 148° revealed that 25 of 42 (60%) participants of this sample did not
have this level of motion available on the involved limb, and 9 of the 25 (36%) reported
moderate to severe difficulty in reaching an overhead shelf on their DASH self-report
form. A Chi square analysis however, revealed no significant relationship between loss of
motion and self-report (p=.08). The HBB and external rotation motions, although
statistically significantly less among BCS, would not be considered to be clinically
deficient. All functional UE tasks can be completed with minimal to no difficulty at the
measured HBB and ER ROM levels. Overall, although ROM is significantly less among
BCS in this study, the values are not clinically relevant, with only a portion of the sample
demonstrating a limitation in one specific functional task. BCS at 6 years following
treatment generally demonstrate ROM at a level similar to their healthly counterparts.
Loss of strength was found to primarily affect BCS who had cancer on their nondominant side. Strength impairments in IR and ER show a 23-25% deficit compared to a
population of women without a history of BC. Additionally, the values of IR and ER
strength of BCS in this study are more than 30% less than published reference values for
a healthy population of similar aged females.62,63 Although methodologies for
measurement differed slightly (flexion resistance at the epicondyle instead of distally at
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the ulnar styloid process,62 and rotation positioning at 45° abduction instead of 90°
abduction62,63), the deficits appear greater than expected through differing methodologies.
Whether these deficits can be definitively linked to a decline in UE function is less clear,
as minimum strength values for completing tasks are difficult to define. As DASH scores
were within normal ranges, that most strength measures among BCS in this study appear
to not be impaired. Overall, BCS demonstrate levels similar to those of women without
breast cancer.
BCS Involved to Non-involved Comparison
Our hypothesis that ROM, strength and muscular endurance in the involved limb
would be less than the non-involved limb was not supported. Although both rotation
motion measures, HBB and ER ROM, were statistically significantly different, the results
showed that dominance was the effect rather than whether the limb underwent BC
treatment. Dominant limbs had less HBB motion and greater ER ROM than nondominant limbs regardless of cancer status, a finding in agreement with other research
examining the effect of dominance on shoulder rotation motion.93 Muscular endurance
appeared to recover to levels of the non-involved limb in this sample of BCS 6 years
following treatment, and these findings are in agreement with a study of 40 BCS
approximately 2 years after treatment who demonstrated similar levels of endurance on
the involved and non-involved limbs.16
It appears that over time, BCS regain motion, strength, and muscular endurance to
similar levels of the non-involved limb. In previous work among a healthy cohort of
women, dominance impacted the HBB measure, flexion strength, and muscular
endurance measured on sub-test 2 of the FIT-HaNSA (see Chapter 3). The cohort of
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BCS did not have greater flexion strength and muscular endurance on their dominant
limb. This could suggest that when BC occurs on the dominant side, the recovery may
not be complete. Because there are no significant limb-limb differences in BCS as would
be expected, when cancer occurs on the non-dominant side, our results suggest a decline
occurs in these measures on the non-involved dominant limb. These findings can be
explained in part by a recent study examining three-dimensional shoulder kinematics and
EMG muscle activity among a group of 155 BCS with unilateral cancer approximately 3
years after treatment (47 participants underwent mastectomy, and 48 axillary lymph node
dissection and/or axillary radiation).101 The BCS were compared to 21 age-matched
healthy women. The authors concluded that all kinematic parameters were abnormal and
EMG output was less among BCS compared to healthy counterparts.101 That both the
involved and non-involved limbs in this study differed from a healthy cohort but not from
each other substantiate that the BC treatment effects can extend into the non-involved
limb. These findings support the need to make clinical comparisons of motion and
strength beyond the non-involved side but should be evaluated against a healthy
population to better assess the level of dysfunction.
The Importance of Muscular Endurance Assessment
Research on muscular endurance among BCS is in the early stages. Two
published studies that have examined this aspect of UE function have used a test which
does not yet have established reliability and validity, yet has shown a decline in
endurance compared to the non-involved limb.14,15 The current study is the first study to
examine the use of the FIT-HaNSA in a population of BCS. Although the findings in this
study show that UE endurance is not impaired compared to a similar healthy population,
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the mean scores on sub-test 2 and 3 of the FIT-HaNSA among all the participants in this
study compare similarly to a study of 17 younger (mean age 32) individuals with
shoulder pathology.29 This would suggest there are some deficits in endurance but that
they appear to be an aging effect not a result of the breast cancer. It is also possible that
no differences between groups were found because this test demonstrated a low level of
responsiveness with large variances among groups. Furthermore, a large ceiling effect
was observed in performing the FIT-HaNSA. Sixty-six to eighty-one percent of the
control group completed the full test duration of 300 seconds and 53-76% of BCS
completed the full test. Examining muscular endurance with a more responsive test
might provide a clearer picture of the level of muscular endurance among BCS.
Limitations
Several limitations in this study may have impacted the results. No information
about whether the BCS in this study had previous rehabilitation was collected. It is
possible that this group had interventions directed toward UE functional return. The
range of time after BC treatment was long (12-271 months). This lengthy time period
may allow normal tissue healing to occur. A longitudinal study analyzing at what point
in time after treatment BCS symptoms improve may give insight into the probable
timeline for return of function. The variance associated with the FIT-HaNSA was large
(>60 seconds), indicating that this measure was not as responsive in identifying those
with decreased endurance as is preferred. Furthermore, the significant ceiling effect of
greater than 50% of all participants finishing the complete test does not allow for
discrimination between levels of muscular endurance.
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Identifying why women who have BC on their non-dominant limb have greater
long term deficits need to be accomplished. Determining why BCS seem to have a
carryover loss in function on their non-involved limb is also important to investigate and
focus rehabilitation efforts. Better clinical measures of muscular endurance, those which
are less variable in responsiveness and without a significant ceiling effect, need to be
investigated. Together, answering these questions can guide early rehabilitation to
prevent long term problems.
Conclusion
The findings in this study suggest that the self-reported level of QOL and UE
function among BCS is lower than women without BC even at 6 years following
treatment. The primary objective limitations were lower ROM measures among BCS
than a control group. This loss of motion may have potential implications on functional
tasks. The differences between BCS and a control population on self-report scales,
combined with objective measures of UE function, indicate a lower level of UE function
among long term BCS. An interesting yet unexpected finding was the effect dominance
plays in BCS UE function. Those found to have BC affecting their non-dominant side
appear to have more persistent ROM and strength deficits compared to BCS affecting
their dominant side.

Copyright © Mary Insana Fisher 2013
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CHAPTER FIVE
A modification of a clinical test used to measure upper body strength and endurance is
presented in this chapter. The experimental design, including participant selection,
dependent measures, data collection procedures and analysis, results, and discussion of
findings, are presented here. The modified Upper Body Strength and Endurance test will
be used to examine muscular endurance in healthy women and women who have been
treated for breast cancer. The new test will be compared to the Functional Impairment
Test – Hand and Neck, Shoulder, and Arm, to determine whether it is a more responsive
and therefore better clinical tool to measure UE muscular endurance.
Introduction
Muscular endurance is an essential component of upper extremity (UE) abilities,
and is one component of UE function within the body structure and function domains of
the International Classification of Functioning, Disability and Health (ICF).7 Few
options exist for the clinician to measure UE muscular endurance, and as a result, it is not
often tested. Options include using an isokinetic testing device, the Functional
Impairment Test – Hand and Neck, Shoulder, and Arm (FIT-HaNSA),29 or the Upper
Body Strength and Endurance Test (UBSE).14
Clinically feasible measures of muscular endurance must be easy to perform, take
a reasonably short amount of time to complete, and require minimal specialized
equipment. Furthermore, these tests should demonstrate sound psychometric properties
including reliability, validity, and responsiveness. Responsiveness is defined as the
ability to measure important difference between groups.102 Isokinetic testing, which has
good psychometric features, can be time intensive and requires expensive equipment. The
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FIT-HaNSA has demonstrated good reliability (ICC=.79-.97)28,29 and convergent
validity(r=.76),28 in research focusing on rotator cuff and shoulder impingement
pathology.28,29 Testing requires an adjustable shelving unit and up to 15 minutes of time
to test one limb. The FIT-HaNSA has not been used to our knowledge in published
research for BCS, however, previous research (Chapter 4) suggests that there is a large
ceiling effect for BCS. This ceiling effect indicates the test may not be demanding
enough. Large variances were present as well, indicating a lower level of responsiveness.
The UBSE was introduced to capture the strength and muscular endurance in BCS.14,15
This test is easy to perform, requires minimal equipment, but can be time consuming; the
total test time varies based on and individual’s fatigue level, but with several stages, can
take over 15 minutes. Data on the psychometric properties of the UBSE are not available
from the literature.
A responsive, easy to execute, and reliable test of UE muscular endurance is
needed to assess this component of UE function. The purpose of this study is to compare
muscular endurance among BCS who completed treatment a minimum of 12 months
earlier, to matched controls. The hypothesis is that BCS will demonstrate lower levels of
muscular endurance than a group of women without BC. A secondary purpose is to
investigate a modification of the Upper Body Strength and Endurance test (mUBSE) for
clinical use in the measurement of muscular endurance. It is expected that the mUBSE
will be less variable compared to the FIT-HaNSA, and demonstrate a greater challenge to
muscular endurance.
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Methods
Subjects
A sample of convenience of 18 BCS and 18 matched participants without BC agreed to
participate in this study. To be included in this study, participants had to be between the
ages of 40 and 69; BCS had to have received at least one of the following BC treatments
at least 12 months prior to data collection: mastectomy, axillary lymph node dissection
(ALND), axillary radiation. Participants were excluded if they had recent (6 month)
history of shoulder, cervical or thoracic spine pathology diagnosed by a physician, or a
history of shoulder, cervical or thoracic surgery. Participants were matched on age and
body mass index (BMI). All participants read and signed a consent form approved by the
Institutional Review Board of the University of Dayton, Dayton, Ohio, prior to starting
the study. One BCS and one control participant were removed from analysis as no
participants who matched on age and BMI were recruited.
Procedure
Each participant came one time to the clinical laboratory for data collection. After
consent was signed, demographic variables of age and arm dominance were recorded,
and height in meters and weight in kilograms to the nearest tenth were measured and
recorded to determine BMI. Heart rate was taken for a baseline measure; this was
repeated before and after each endurance test. Each participant then completed a 5
minute warm-up on the treadmill, with 1 pound wrist weights. Participants were
instructed to walk at a comfortable pace and swing their arms to include UE muscular
warm-up.
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Following warm-up, the participant was instructed in testing procedures, including
maximal voluntary isometric contraction (MVIC) testing using a hand-held
dynamometer. Strength testing was performed at 6 different time points during the
testing. At each time point, 3 trials of MVIC were recorded and averaged. The first 2
testing trials were utilized for familiarization and baseline assessment. The trial which
had the greatest mean and had less than a 10% coefficient of variance was then used for
comparison of later strength testing for muscle recovery. The second trial was used as
baseline 65% of the time.
Estimated 1 repetition maximum (1RM), a submaximal repetition test, was used
to determine a 1RM value. Each participant was given a heavy load, and the number of
repetitions correctly performed was counted. The estimation is based on the following
formula where x is the number of repetitions completed:23
Estimated 1RM = weight lifted/(1.0278-.0278x)
Endurance testing was randomized such that either the FIT-HaNSA or the
mUBSE was completed first. After completing each endurance test, the participant was
asked to rate her level exertion using the Borg CR-10.103 A 25 minute minimum rest
break was given between the endurance testing procedures to allow for muscle
recovery.104 During this time, participants completed 5 self-report questionnaires. After
25 minutes, a brief warm-up of the UE was completed prior to the final endurance test.
To be able to begin endurance testing, the strength measurement had to reflect a value of
at least 90% of baseline to ensure that muscle recovery had occurred.104 If the participant
could not achieve this 90% level, additional rest and/or warm-up was provided, until the
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90% level could be reached. Heart rate was taken, and if it had not returned to baseline,
further rest was also provided.
In a pilot study of 5 healthy females, data on 10 limbs was collected to assess testretest reliability. MVIC strength testing and the mUBSE demonstrated acceptable
reliability, ICC=.76 and .75 respectively.

Figure 5.1: Data Collection Procedure
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Dependent Variables
Self-report Scales
Activity level was measured using the 7-item International Physical Activity
Questionnaire (IPAQ), which has good test-retest reliability (r= .70-.90).84 Quality of life
was measured using the Functional Assessment of Cancer Therapy – Breast (FACT-B),
which has good construct validity (r=.90) and test-retest reliability (ICC=.88).33 This
scale is comprised of 27 questions making up the FACT-G (General cancer quality of life
scale) plus 9 additional items specific to breast cancer for a score of ranging from 0
to144; higher values indicate a higher quality of life. Self-reported UE disability was
assessed with the Disabilities of the Arm, Shoulder, and Hand (DASH), a reliable and
valid39,40 30 question disability scored 0-100, with lower scores indicating less disability.
The Piper Fatigue Scale, a reliable and valid scale frequently used in the cancer
population to assess levels of fatigue resulting from treatment, has 22 scaled questions
related to levels of fatigue.105-107 The scale is scored 0-10, with lower scores indicating
lower fatigue.106 The Physical Activity Assessment Inventory (PAAI) is a new scale
intended to assess levels of self-efficacy in relation to physical activity among BCS,
scored 0-100 with higher scores indicating higher self-efficacy levels.108 Preliminary
research has shown this scale to be reliable (Cronbach’s alpha=.95).108
Objective Clinical Measures:
Perceived Exertion: Perceived exertion was measured using the BORG CR-10, a 1-10
scale with higher scores indicating more perceived exertion, with good reliability and
validity.103 Perceived exertion can indicate how strenuous an activity is.103 The levels of
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the BORG CR-10 will be compared after each endurance test to provide information
about the tests.
Strength: The strength of the shoulder abduction was measured using hand-held
dynamometry. The hand held dynamometer (Lafayette Manual Muscle Test System,
Lafayette Instruments, Lafayette, IN) was set in a fixed bracket to ensure consistent
resistance for all participants, with the participant seated, and arm positioned at 90°
abduction in approximately 30° of the frontal plane.7 (Figure 5.2) Each participant was
instructed to generate force to a maximal level over 5 seconds.7,63 Two submaximal
practice trials were completed prior to testing; 10 seconds rest was given between trials.
The peak force produced for each trial was recorded, and an average of 3 trials was used
for analysis.54 Baseline testing included two sessions of 3 trials; the highest average value
with ≤10% coefficient of variance was used as the baseline strength measure.

Figure 5.2: Strength Testing Position
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Endurance
FIT-HaNSA: Participants completed sub-tests 2 and 3 of the FIT-HaNSA
following a previously established protocol for performance and termination of testing.29
The FIT-HaNSA demonstrates good-excellent reliability,24 ranging from .89-.99,28,29 and
good convergent validity.28
mUBSE: This endurance test modifies the UBSE14 by removing the stages of
incremental increase in resistance. In this modified version, the participant uses 50% of
her 1RM estimated weight for the combination upright row/shoulder press motion. This
weight is repeatedly lifting through the motion until failure. Criteria for stopping the test
include: 1) Participant can no longer continue lifting weight; 2) Participant cannot reach
her maximum high point 2 times consecutively; 3) Participant cannot maintain cadence
of lift (2 beats up/2 beats down); and 4) Participant demonstrates extremely poor form of
lift. The number of repetitions completed is recorded. Each arm is tested separately as
pilot testing showed that it was difficult for participants to continue on one arm when the
other fatigued which would limit evaluation of limb differences in the BCS group. See
Figures 5.3-5.5.

73

Figure 5.3:
Beginning mUBSE

Figure 5.4:
Mid-point mUBSE

Figure 5.5:
Top position mUBSE

Statistical Analysis
An a priori analysis of power was completed on pilot data. The mean
(SD) of a control group completing the mUBSE was 19 (4), and for BC was
14(1). Conservative values were used to calculate power and effect size,
increasing the BC mean (SD) to 15(4). With these values, the power analysis
conducted at alpha = .05, revealed a true power of 82%; 14 participants per group
(28 total) would provide an effect size of 1.0.
Data were analyzed using IBM SPSS Statistics 19 (New York, NY).
Descriptive statistics were calculated for all variables of self-report scales, and
muscular endurance for each group. To confirm that the characteristics of each
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group were similar, independent samples t-tests were used to analyze age, BMI
and activity level.
Whether the dominant or the non-dominant limb was the involved limb in
BCS was recorded for data analysis. This is based on findings from previous
research in Chapter 3 which show that dominance has an effect on at least one
measure in ROM, strength, unilateral muscular endurance tasks. Therefore, the
BCS group was subdivided into two groups: involved dominant or involved nondominant. Comparisons were then made for like limbs: involved dominant BCS
to dominant control, and involved non-dominant to non-dominant control.
Significance for all analyses was set a priori at p≤.05
To examine differences between BCS and the control group, analysis of
variance (ANOVA) models were constructed for the DASH, FACT-B, Piper
Fatigue Scale, PAAI, and the bilateral muscular endurance test sub-test 3 of the
FIT-HaNSA. If significance was found (p≤.05), then Tukey post hoc testing was
used to determine which group was involved. To examine differences between
the BCS and controls for the mUBSE and sub-test 2 of the FIT-HaNSA, we ran
separate ANOVAs. The involved dominant limb of BCS was compared to the
dominant limb of controls, and the involved non-dominant limb of the BCS to the
non-dominant limb of the control group. Because only two groups were
compared, the involved limb to the respective limb of the control group, no post
hoc testing was necessary
The level of responsiveness of mUBSE was compared to the FIT-HaNSA
by examining the level of variance of each test. We ran separate ANOVAs
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comparing the involved limb to the non-involved limb of BCS, and evaluated the
F-statistic of each endurance test. Secondary analyses with independent samples
t-tests included comparison of percent change in MVIC and heart rate levels, and
the level of perceived exertion using BORG CR-10.
Results
Participant characteristics are detailed in Table 5.1. Participant
demographics of age and body mass index (BMI) were similar (p>.05). BCS had
a significantly greater activity level than the control group (p=.049). (Table 5.1)
Among BCS, the mean duration since surgical treatment was 85 months (range
17-217); 14 underwent a mastectomy, 12 ALND, and 4 had axillary radiation. Of
these, 5 BCS had both a mastectomy and ALND, and 3 underwent all three
procedures.
Comparison of BCS to the Control Group
No significant differences were found between BCS and the control group
on any of the self-report scales (p=.07-.40). (Table 5.2) No significant
differences were found between the BCS and the control group on either the FITHaNSA or the mUBSE (p=.44-.72). (Table 5.3)
Comparison of the FIT-HaNSA to the mUBSE
To compare the levels of variability of the FIT-HaNSA and mUBSE, the
F-statistic of an ANOVA was evaluated using repeated measures general linear
models comparing the involved limb to the non-involved limb of BCS. Both Fstatistics were 2.5.
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The percent change in MVIC and HR after each endurance test was used
to evaluate how demanding each test was. The MVIC and HR after each test was
subtracted from the pre-test value to calculate the change score. Only the percent
change in MVIC for mUBSE on the dominant side resulted in a statistically
significant difference between groups on the independent samples t-tests. The
control group (22±14%) had a statistically greater drop in endurance than the
involved dominant BCS (<1±20%) (p=.01). The percent change in MVIC on the
non-dominant mUBSE was not statistically significant between groups. (Table
5.4) The percent change in heart rate pre- to post on the mUBSE for BCS
(29±16%) and controls (30±14%) was not statistically different. The percent
change in heart rate pre- to post on the FIT-HaNSA for BCS (27±18%) and
controls (31±15%) also was not statistically significant. The BORG CR-10
perceived exertion levels were also not statistically different for BCS and controls
on either the mUBSE (9±1 and 8±1, respectively) or the FIT-HaNSA (7±1 and
8±2, respectively).
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Table 5.1: Baseline Characteristics for Group Comparisons
Control (n=17)
BCS (n=17)

Age, years
58 (7)
58 (7)

BMI
28.5 (5.5)
28.7 (5.3)

IPAQ (mets)
2107 (1554)
4392(4339)

Abbreviations: BMI = Body Mass Index; IPAQ (International Physical Activity
Questionnaire

Table 5.2: Self-Report Scales
Control (n=17)
BCS Inv Dom (n=6)
BCS Inv ND (n=11)

FACT-B
103.9 (11.4)
119.6 (10.3)
107.9 (18.2)

DASH
6.0 (5.5)
9.8 (16.1)
15.7 (16.0)

Piper
2.1 (1.4)
2.6 (1.6)
3.5 (2.2)

PAAI
74.2 (19.1)
65.9 (25.6)
62.8 (25.5)

Abbreviations: FACT-B=Functional Assessment of Cancer Therapy-Breast; DASH=Disabilities of
Arm, Shoulder, and Hand; PAAI=Physical Activity Assessment Inventory; BC=breast cancer; Inv
Dom=Involved Dominant; Inv Non-dom=Involved Non-dominant

Table 5.3: Muscular Endurance
mUBSE
Control (n=17)
BCS (n=17)

FIT-HaNSA sub-test 2

Dominant

Non-dominant

18 (5)
19 (12)

15 (4)
16 (4)

Dominant

Non-dominant

254 (75)
266 (65)

233 (86)
257 (64)

FITHaNSA
subtest 3

273 (54)
258 (72)

BCS Involved Dominant n=6; BCS Involved Non-dominant n=11
For BCS, all endurance values are on the involved limb, except Fit 3, which is a bilateral
task.
mUBSE measured in repetitions; FIT-HaNSA in seconds

Table 5.4 Percent Change MVIC pre-post mUBSE and FIT-HaNSA
Dominant
Control (n=17)
BCS (n=17)

22 (14%)
<1 (20%)

mUBSE
Non-dominant

19 (15%)
16 (9%)

FIT-HaNSA
Dominant
Non-dominant

23 (15%)
14 (15%)

17 (19%)
12 (22%)

Abbreviations: mUBSE = modified Upper Body Strength and Endurance test; FIT-HaNSA
= Functional Impairment Test – Hand and Neck, Shoulder, Arm
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Discussion
The primary aim in this study, to investigate levels of UE muscular endurance
between a sample of BCS and a control group, revealed no differences between
the groups on either measure of muscular endurance. Analyses of self-report
measures examining quality of life, UE function, fatigue, and self-efficacy
regarding physical activity also showed no differences between groups. The
findings of this study indicate that BCS 7 years after treatment appear to achieve a
full return of UE function and endurance.
Comparison of BCS to the Control Group
In examining self-report scales, although no differences were found
between BCS and the control group, perceptions of quality of life and UE
function trended toward differences. BCS in this study reported a higher FACT-B
score (p=.07), indicating a higher perceived quality of life than the control group.
The FACT-B is written specifically for BCS with questions unique to a person
who has had cancer. It is possible that women who had not had cancer could not
accurately answer the questions. Although the scale can be scored with blank
answers, it may be that too many answers were left blank, making any assessment
of quality of life among this group inaccurate. Whether the control group had
difficulty answering these questions or the number of questions left blank resulted
in an inaccurate assessment of QOL, the FACT-B may not be interpretable.
While the DASH scores for BCS were higher than the control group
(p=.07), these scores are within a range of what could be considered normal
scores. Two large studies examining typical DASH scores among a population
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without UE pathology reported scores between 10.1(14.7)45 - 14.3(14.9).46
Despite a trend toward a difference indicating a more disability among BCS, the
findings in this study reveal that recovery of function occurs by 7 years after
treatment.
Endurance is one component of UE function, and the findings of this study
show that women who have had treatment for BC on average 7 years prior
demonstrate levels of endurance comparable to women without BC. No studies
have investigated muscular endurance at this point in the recovery of BCS for
comparison. One study examined muscular endurance using the Upper Body
Strength and Endurance test in 186 BCS 18 months after treatment and reported
that 40% continued to demonstrate a loss endurance compared to the noninvolved limb.15 Further evidence that BCS recover muscular endurance is that
the values on the FIT-HaNSA among the BCS in this study were actually higher
than those of the control group. The large variance associated with this test may
have made any differences between groups difficult to appreciate. Values on the
FIT-HaNSA among a similar group of 42 BCS were slightly lower than seen in
this study (see Chapter 4). These findings may be explained in part by the activity
level among this sample of BCS. The BCS reported high levels of activity on the
IPAQ; a mean score of 4392 mets is categorized as a high activity level.84
Whether comparing the results of this study to previous work or to the control
group, BCS appear to have normal levels of muscular endurance.
Breast cancer survivors who are, on average, 7 years removed from BC
treatment, have regained a level of UE function and endurance similar to that of
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women without a history of BC. Furthermore, an active lifestyle as reported by
this sample may mitigate any long range effects on UE endurance.
Comparison of the FIT-HaNSA to the mUBSE
The units of measure and magnitude of results of the FIT-HaNSA and
mUBSE greatly differ, making direct comparisons of their respective variances
invalid. The FIT-HaNSA scores ranged from 92-300 seconds, with standard
deviations as large as 86, whereas the mUBSE scores ranged from 11-44, with
standard deviations no greater than 12. The F-statistic in an ANOVA tests
whether the variances of two populations are significantly different.24 The Fstatistic was examined for each endurance test using an ANOVA comparing the
involved limb to the non-involved limb in BCS. For both the FIT-HaNSA and the
mUBSE, the F-statistic was 2.5, suggesting that both tests have similar variance.
Although not statistically significant, it is interesting to note that the mean
endurance on the involved limb was less than the non-involved on the mUBSE, as
would be expected, but greater than the non-involved on the FIT-HaNSA. This
may suggest that the mUBSE is more accurately assessing the endurance as the
direction of difference is as expected in the involved limb. The ceiling effects on
the FIT-HaNSA remain high, with as many as 71% (12/17) of BCS and 76%
(13/17) of the control group reaching the full test duration of 300 seconds. The
mUBSE without a ceiling effect offers an alternative measure of muscular
endurance.
To examine whether one endurance test was a greater physiological
challenge than the other, the percent change in MVIC and heart rate, and the
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levels of the BORG CR-10 perceived exertion were examined. The significant
finding that the percent change in MVIC for the mUBSE was greater among the
control group than the BCS may be explained by the presence of highly active
BCS as indicated by high IPAQ scores; this BCS subgroup had more than twice
as high of an activity level measured on the IPAQ (5235±4122) compared to the
controls (2107±1554). That this percent change of MVIC was the only significant
finding out of 4 variables examining MVIC change, suggests that both tests
similarly challenge muscular endurance. The percent change in heart rate was not
different between groups for either endurance test, indicating neither test
challenges the cardiovascular system more than another. Mean BORG CR-10
levels were not different, suggesting that each test was equally difficulty. Both
tests were perceived as a hard activity. These findings indicate that the mUBSE is
not as challenging as the FIT-HaNSA.
That the mUBSE compared similarly in our study to the FIT-HaNSA,
which has been more extensively studied in the general shoulder population and
demonstrates good reliability and validity with self-report scales, suggests that
this test of muscular endurance may be used in lieu of the FIT-HaNSA. The test
takes less than 5 minutes to perform, and because it is a repetition to failure test,
has no ceiling effects. These features may make it an attractive alternative to the
FIT-HaNSA in clinical practice.
Limitations
This study had a limited number of participants, although an a priori
power analysis of the mUBSE indicated the sample size was adequate. The long
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survival period among the BCS of 7 years (range 17-217 months) may have
allowed full healing to occur. The BCS in this sample were highly active,
exceeding the activity level of the control group. It is possible this group was a
not a true representation of BCS in term of this activity level.
Future research into UE endurance among BCS should focus on more
immediate post treatment time periods to determine how long deficits persist.
Continued comparisons to a healthy population need to be made to fully
appreciate any differences. Better tests of UE muscular endurance need to be
investigated.
Conclusion
Breast cancer survivors who are 7 years post treatment appear to have
similar levels of muscular endurance to that of women without a history of BC.
Furthermore, these women report a level of quality of life and UE function similar
to healthy women. Less variable clinical measures of muscular endurance have
yet to be developed, but the mUBSE presents a possible alternative to the FITHaNSA in testing upper extremity muscular endurance as it takes less time to
administer and suffers no ceiling effects.

Copyright © Mary Insana Fisher 2013
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CHAPTER SIX
Despite research documenting the deficits in upper extremity (UE)
function in survivors of breast cancer (BCS) post-operatively and beyond the first
year of treatment, few studies have compared BCS to a sample of healthy controls
using a battery of functional tests. The impairments of BCS have not been
examined in light of any decline which occurs with normal aging. Whether selfreported quality of life (QOL) and UE function, range of motion (ROM), strength,
and muscular endurance deficits in BCS are due to aging or breast cancer (BC)
treatment has not been fully investigated. The need to understand the level of
impairment in long term BCS in comparison to women without BC shoudl be
established. The primary purpose of this research was to compare UE function
among long term BCS and similar aged women without cancer. We expected that
BCS who received treatment more than 12 months previously would demonstrate
less motion, strength, and muscular endurance and higher levels of self-reported
UE disability as well as lower levels of QOL than similar aged women without
BC.
Typical Measures of Upper Extremity Function in Healthy Women 30-69
In making comparisons between BCS and women without BC, it is
important to understand whether subjective and objective measures of UE
function change with age, or vary limb to limb based on dominance. An
understanding of perceived QOL among healthy women is also necessary. We
undertook to describe QOL and UE function among women without BC ages 3069. We hypothesized that as women aged, there would be declines in all
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measures, and that the dominant limb would show less ROM, and greater strength
and muscular endurance than the non-dominant limb.
In examining UE function among 79 women age 30-69 without BC,
available UE ROM varied little as women aged, with statistical significance found
only for dominant flexion ROM between women in their 30’s and women in their
60’s. This difference was not clinically relevant however, as the mean flexion
among 60 year old women, at 148°, is great enough to complete even high level
UE functional tasks.92 All other motion, strength, and muscular endurance
variables did not differ across the four decades studied.
Dominance appears to play a role in ROM and strength measures. The
hand behind back motion, representing some level of internal rotation ROM, was
less on the dominant side compared to the non-dominant, and is consistent with
other research.78,90,93 This, however, was the only motion wherein dominance
played a role. Shoulder flexion on the dominant side was significantly stronger
than the non-dominant side, which may have implications for clinical strength
testing in women with breast cancer. These differences did not impact perceived
function levels, as self-report functional levels are unimpaired in these women.
The impact of dominance on muscular endurance of the UE has not been
extensively studied, but in our study, muscular endurance was greater on the
dominant limb. Intuitively, this may be because the dominant limb tends to be
used to a greater extent in daily activities, and therefore type I endurance muscle
fibers may be enhanced.
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A Comparison of Upper Extremity Function Between BCS and Healthy Controls
Research has suggested that long term BCS demonstrate declines in UE
function beyond the time required for normal healing,17,73 however, these are
comparisons to a premorbid status which does not account for change over time,
or to a contralateral limb, rather than to a population without BC. The purpose of
this study was to compare QOL and UE function among women who had been
treated for breast cancer at least 12 months prior to data collection to a sample of
healthy women. It was believed that BCS would show deficits in self-reported
QOL and UE function, and measures of ROM, strength, and muscular endurance.
A secondary purpose was to compare ROM, strength, and muscular endurance of
the involved limb to the non-involved limb of BCS. We believed the involved UE
would demonstrate lower levels on all measures than the non-involved limb.
All self-reported measures of QOL and UE function were statistically
significantly lower among BCS compared to a healthy sample. Although BCS
report higher levels of disability than women without BC, the value reported is
similar to the population at large.45,46 BCS also demonstrated significantly less
motion than women without BC. However, these differences appear to be
minimal and may have no clinical relevance as the moderately lower values
demonstrated by BCS would still allow daily tasks to be completed. Strength
deficits appear when the cancer is on the non-dominant limb. These deficits,
however, may not clearly impact functional tasks, as DASH scores remained
within a range of normal. Muscular endurance did not appear to be affected by
BC treatment, suggesting that over time, women recover to normal levels.
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Limb to limb comparisons within the BCS revealed no relevant
differences related to BC treatment. Both HBB and ER were significantly less on
the dominant limb regardless of whether the limb underwent BC treatment. No
other differences were found. These findings may implicate a carry-over effect of
treatment to the non-involved limb as the population without BC demonstrated
greater strength and endurance in the dominant limb. Therefore, the fact there is
no expected difference could indicate an impairment.
Muscular Endurance Among Women
Muscular endurance is not easily measured in the clinic due to a lack of
valid and reliable measures. The Functional Impairment Test – Hand, and Neck,
Shoulder, Arm (FIT-HaNSA) demonstrated a high variance, suggesting that the
level of responsiveness is low, as well as high ceiling effects. The final study
examined a new clinical test of UE function. The modified Upper Body Strength
and Endurance test (mUBSE) was compared to the FIT-HaNSA in both healthy
controls and BCS in a matched study. We hypothesized that BCS would
demonstrate lower levels of UE endurance than matched controls. Furthermore,
we hoped to see that this new test would be more responsive than the FITHaNSA. Results, however, indicated that BCS have nearly the same level of UE
endurance as women without BC, suggesting that long term BCS recover
muscular endurance over time. The mUBSE, although not suffering from ceiling
effects, did not demonstrate more responsiveness than the FIT-HaNSA.
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Conclusion
Overall, BCS 6 years removed from treatment recovered UE function to
levels similar to a population of women without BC. Self-reported QOL and UE
function was lower among BCS than a sample of women who had not had BC but
remains within the range of normal. Some deficits in motion and strength are
present among long term BCS, but are likely not clinically relevant. Breast
cancer survivors can recover UE function over time to levels within normal
ranges.

Copyright © Mary Insana Fisher 2013

88

APPENDICES
Appendix A

89

Appendix B

Consent to Participate in a Research Study

A comparison of upper extremity motion, strength, endurance,
function, and quality of life between female breast cancer survivors
and healthy controls
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH?
You are being invited to take part in a research study about arm motion, strength,
endurance and use in women. You are being invited to take part in this research study
because you are a female between ages 30 and 69. If you volunteer to take part in this
study, you will be one of about 200 people to do so.
WHO IS DOING THE STUDY?

The person in charge of this study is Mary Fisher PT, a student of University of Kentucky,
Department of Rehabilitation Sciences. She is being guided in this research by Tim Uhl,
PhD ATC PT. There may be other people on the research team assisting at different
times during the study.

WHAT IS THE PURPOSE OF THIS STUDY?
By doing this study, we hope to learn about the motion, strength, endurance, use of the
arm and shoulder, and the quality of life among women who have had breast cancer
treatment and compare that information to women who have not had any history of breast
cancer or shoulder injury.
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS STUDY?
If you are under the age of 30, or older than 69, you may not take part in this study. If you
are a male you may not participate in the study. If you had shoulder, neck or back
surgery you may not participate in the study. If you have had an injury to your shoulder,
neck, or back in the last 6 months you may not participate in this study. If you have had
breast cancer that has been limited to lumpectomy and/or sentinel lymph node biopsy
you cannot participate in this study.
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?
The research procedures will be conducted at the University of Kentucky Musculoskeletal
Research Laboratory. This lab is located on the second floor, room 222 of the Charles T.
Wethington Building connected to the University of Kentucky Clinic at 900 South
Limestone. You will be asked to come to the Musculoskeletal lab 1-2 times during the
study. Each of those visits will take about 90 minutes. The total amount of time you will
be asked to volunteer for this study is 3 hours over the next 1-2 weeks.
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WHAT WILL YOU BE ASKED TO DO?
You will complete five questionnaires about your general health, your arm use, and how
you feel. The investigator will take measurements of your arm motion using devices
which measure the motion, strength and endurance of your arm.
Questionnaires:
You will complete a general medical questionnaire asking you about your health status,
previous surgeries, and any medications you are taking, to see if you can participate in
this study. Two questionnaires will ask you about how you use your arm in daily
activities. Another questionnaire will ask you about how you feel in general. The last
questionnaire will ask you about your overall activity level.
Range of Motion Measurements:
Your arm range of motion will be measured on both sides in three directions, elevation,
inward and outward rotation. Shoulder elevation will be measured while upright and you
will be asked to lift your arm up in front of you high a possible. Shoulder inward rotation
will be measured while you are standing, and you will be asked to place your hand
behind your back as high up the spine as possible. Shoulder outward rotation will be
measured while lying on your back with your arm out to the side and your elbow resting
on two towels. You will rotate your arm toward the floor by your head. A picture will be
taken of your arm once you have completed each motion. The angle of motion will be
measured from this picture. Once the measurement has been completed, the picture will
be destroyed.
Strength Measurements:
Your arm strength will be measured on both sides in the same directions as your motion.
A device called a dynamometer will be used to measure your strength and it will be
attached to your wrist with an inelastic nylon strap. We will place your arm in a position
and you will push against the strap for 5 seconds as hard as you can. This will be
repeated twice in all directions on both arms. You will be given a 15 -30 second break
between maximal efforts to allow for recovery. You will be given two practice trials and
then we will record the two trials of maximal force you exert in each direction. These
measures will be taken while seated. For shoulder elevation, you will lift your arm as you
did for the range of motion measure. For the inward and outward rotation strength
measures, your arm will be at your side and you will rotate toward your stomach or away
from your stomach.
Arm Endurance:
You will be asked to lift a 2 pound weight from eye level down about 10 inches and back
up as long as you can complete the task, up to 5 minutes with each arm. Lastly, you will
be asked to fasten and unfasten bolts in a plate above your head for as long as you can
complete the task, up to 5 minutes.
We may request that you be contacted after the study is completed, for further follow-up
or future research. If you decline, no further contact with you will be made.
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WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?
None of the measurements will be dangerous to you. You may experience minor sideeffects of muscle soreness from pushing hard against the force device or stretching your
muscles. You may experience minor bruises from pushing hard against the force device.
These side-effects should resolve within a day.
Please report any side-effects to the Principal Investigator, Mary Fisher, at 937-238-0633.
There is always a chance that any medical treatment can harm you, and the
investigational treatment in this study is no different. In addition to the risks listed above,
you may experience a previously unknown risk or side effect.
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY?
There is no guarantee that you will get any benefit from taking part in this study. Your
willingness to take part, however, may, in the future, help researchers and clinicians
better understand and/or treat other breast cancer survivors. You will be provided a copy
of your results along with a standardized exercise program to help you improve in any
deficits revealed from testing.
DO YOU HAVE TO TAKE PART IN THE STUDY?
If you decide to take part in the study, it should be because you really want to volunteer.
You will not lose any benefits or rights you would normally have if you choose not to
volunteer. You can stop at any time during the study and still keep the benefits and rights
you had before volunteering.
IF YOU DON’T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER
CHOICES?
If you do not want to be in the study, there are no other choices except not to take part in
the study.
WHAT WILL IT COST YOU TO PARTICIPATE?
The cost to you for participation in this study requires that you travel to and pay parking
costs for the University of Kentucky Musculoskeletal Lab. There are no other costs
associated with your participation.
WHO WILL SEE THE INFORMATION THAT YOU GIVE?
We will make every effort to keep private all research records that identify you to the
extent allowed by law.
Your information will be combined with information from other people taking part in the
study. When we write about the study to share it with other researchers, we will write
about the combined information we have gathered. You will not be personally identified in
these written materials. We may publish the results of this study; however, we will keep
your name and other identifying information private.
We will make every effort to prevent anyone who is not on the research team from
knowing that you gave us information, or what that information is. First, we will give
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everyone a code number and remove their names from most documents. All information
will be kept in a locked lab on a password protected computer. The information that we
obtain from you in this study will be included in a larger database in the Research Lab.
The information that we obtain from you may be included in future studies for other types
of comparisons. However, the information used will have no identifiable link to your
personal identification.
This study is being conducted in conjunction with the University of Dayton, and the
Institutional Review Board at the University of Dayton may request access to the data
collected at the University of Kentucky for review.
You should know, however, that there are some circumstances in which we may have to
show your information to other people. For example, the law may require us to show your
information to a court or to tell authorities if you report information about a child being
abused or if you pose a danger to yourself or someone else. Officials from the University
of Kentucky may look at or copy pertinent portions of records that identify you.
CAN YOUR TAKING PART IN THE STUDY END EARLY?
If you decide to take part in the study you still have the right to decide at any time that
you no longer want to continue. You will not be treated differently if you decide to stop
taking part in the study.
The individuals conducting the study may need to withdraw you from the study. This may
occur if you are not able to follow the directions they give you, or if they find that your
being in the study is more risk than benefit to you. There are no expected adverse
effects should you withdraw from this study.
ARE YOU PARTICIPATING OR CAN YOU PARTICIPATE IN ANOTHER RESEARCH
STUDY AT THE SAME TIME AS PARTICIPATING IN THIS ONE?
You may take part in this study if you are currently involved in another research study. It
is important to let the investigator/your doctor know if you are in another research study.
You should also discuss with the investigator before you agree to participate in another
research study while you are enrolled in this study.
WHAT HAPPENS IF YOU GET HURT OR SICK DURING THE STUDY?
If you believe you are hurt or if you get sick because of something that is due to the
study, you should call Mary Fisher at 937-238-0633 immediately. Mary Fisher will
determine what type of treatment, if any, that is best for you at that time.
It is important for you to understand that the University of Kentucky does not have funds
set aside to pay for the cost of any care or treatment that might be necessary because
you get hurt or sick while taking part in this study. Also, the University of Kentucky will not
pay for any wages you may lose if you are harmed by this study.
The medical costs related to your care and treatment because of research related harm
will be your responsibility but may be paid by your insurer if you are insured by a health
insurance company (you should ask your insurer if you have any questions regarding
your insurer’s willingness to pay under these circumstances).
A co-payment/deductible from you may be required by your insurer or Medicare/Medicaid
even if your insurer or Medicare/Medicaid has agreed to pay the costs). The amount of
this co-payment/deductible may be substantial.
You do not give up your legal rights by signing this form.
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WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY?
You will not receive any rewards or payment for taking part in the study. However, if you
are interested, we can provide you with a standardized exercise program to address any
strength and motion deficits you may have.
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR COMPLAINTS?
Before you decide whether to accept this invitation to take part in the study, please ask
any questions that might come to mind now. Later, if you have questions, suggestions,
concerns, or complaints about the study, you can contact the investigator, Mary Fisher at
937-238-0633. If you have any questions about your rights as a volunteer in this
research, contact the staff in the Office of Research Integrity at the University of Kentucky
at 859-257-9428 or toll free at 1-866-400-9428. We will give you a signed copy of this
consent form to take with you.
WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT MIGHT
AFFECT YOUR DECISION TO PARTICIPATE?
If the researcher learns of new information in regards to this study, and it might change
your willingness to stay in this study, the information will be provided to you. You may be
asked to sign a new informed consent form if the information is provided to you after you
have joined the study.
WHAT ELSE DO YOU NEED TO KNOW?
You will be told if any new information is learned which may affect your shoulder or arm,
or influence your willingness to continue taking part in this study.

_____________________________________________
Signature of person agreeing to take part in the study

____________
Date

_____________________________________________
Printed name of person agreeing to take part in the study
_____________________________________________
Name of [authorized] person obtaining informed consent
_________________________________________
Signature of Investigator
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____________
Date

Appendix C

INTERNATIONAL PHYSICAL ACTIVITY
QUESTIONNAIRE
(August 2002)
SHORT LAST 7 DAYS SELF-ADMINISTERED
FORMAT
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years)
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4
questionnaires. Long (5 activity domains asked independently) and short (4
generic items) versions for use by either telephone or self-administered methods
are available. The purpose of the questionnaires is to provide common
instruments that can be used to obtain internationally comparable data on
health–related physical activity.
Background on IPAQ
The development of an international measure for physical activity commenced in
Geneva in 1998 and was followed by extensive reliability and validity testing
undertaken across 12 countries (14 sites) during 2000. The final results suggest
that these measures have acceptable measurement properties for use in many
settings and in different languages, and are suitable for national populationbased prevalence studies of participation in physical activity.
Using IPAQ
Use of the IPAQ instruments for monitoring and research purposes is
encouraged. It is recommended that no changes be made to the order or wording
of the questions as this will affect the psychometric properties of the instruments.

Translation from English and Cultural Adaptation
Translation from English is supported to facilitate worldwide use of IPAQ.
Information on the availability of IPAQ in different languages can be obtained at
www.ipaq.ki.se. If a new translation is undertaken we highly recommend using
the prescribed back translation methods available on the IPAQ website. If
possible please consider making your translated version of IPAQ available to
others by contributing it to the IPAQ website. Further details on translation and
cultural adaptation can be downloaded from the website.
Further Developments of IPAQ
International collaboration on IPAQ is on-going and an International Physical
Activity Prevalence Study is in progress. For further information see the IPAQ
website.
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More Information
More detailed information on the IPAQ process and the research methods used
in the development of IPAQ instruments is available at www.ipaq.ki.se and
Booth, M.L. (2000). Assessment of Physical Activity: An International
Perspective. Research Quarterly for Exercise and Sport, 71 (2): s114-20. Other
scientific publications and presentations on the use of IPAQ are summarized on
the website.
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INTERNATIONAL PHYSICAL ACTIVITY
QUESTIONNAIRE
We are interested in finding out about the kinds of physical activities that
people do as part of their everyday lives. The questions will ask you about
the time you spent being physically active in the last 7 days. Please
answer each question even if you do not consider yourself to be an active
person. Please think about the activities you do at work, as part of your
house and yard work, to get from place to place, and in your spare time for
recreation, exercise or sport.
Think about all the vigorous activities that you did in the last 7 days.
Vigorous physical activities refer to activities that take hard physical effort
and make you breathe much harder than normal. Think only about those
physical activities that you did for at least 10 minutes at a time.
1.

During the last 7 days, on how many days did you do vigorous
physical activities like heavy lifting, digging, aerobics, or fast
bicycling?
_____ days per week
No vigorous physical activities

2.

Skip to question 3

How much time did you usually spend doing vigorous physical
activities on one of those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

Think about all the moderate activities that you did in the last 7 days.
Moderate activities refer to activities that take moderate physical effort
and make you breathe somewhat harder than normal. Think only about
those physical activities that you did for at least 10 minutes at a time.
3.

During the last 7 days, on how many days did you do moderate
physical activities like carrying light loads, bicycling at a regular
pace, or doubles tennis? Do not include walking.
_____ days per week
No moderate physical activities
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Skip to question 5

4.

How much time did you usually spend doing moderate physical
activities on one of those days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

Think about the time you spent walking in the last 7 days. This includes
at work and at home, walking to travel from place to place, and any other
walking that you might do solely for recreation, sport, exercise, or leisure.
5.

During the last 7 days, on how many days did you walk for at least
10 minutes at a time?
_____ days per week
No walking

6.

Skip to question 7

How much time did you usually spend walking on one of those
days?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

The last question is about the time you spent sitting on weekdays during
the last 7 days. Include time spent at work, at home, while doing course
work and during leisure time. This may include time spent sitting at a
desk, visiting friends, reading, or sitting or lying down to watch television.
7. During the last 7 days, how much time did you spend sitting on a
week day?
_____ hours per day
_____ minutes per day
Don’t know/Not sure

This is the end of the questionnaire, thank you for
participating.
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Appendix D

FACT-B
Below is a list of statements that other people with your illness have said
are important. Please circle or mark one number per line to indicate
your response as it applies to the past 7 days.

PHYSICAL WELL-BEING
Not at
all

I have a lack of energy
I have nausea
Because of my physical condition, I
have trouble
meeting the needs of my family
I have pain
I am bothered by side effects of
treatment
I feel ill
I am forced to spend time in bed
I feel ill
I am forced to spend time in bed

A little
bit

Somewhat

Quite a
bit

Very
much

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

0
0

1
1

2
2

3
3

4
4

0
0
0
0

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

A little
bit

Somewhat

Quite a
bit

0
0
0
0
0

1
1
1
1
1

2
2
2
2
2

3
3
3
3
3

4
4
4
4
4

0

1

2

3

4

0

1

2

3

4

SOCIAL/FAMILY WELL-BEING
Not at
all

I feel close to my friends
I get emotional support from my family
I get support from my friends
My family has accepted my illness
I am satisfied with family
communication about my
illness
I feel close to my partner (or the person
who is my main
support)

Very
much

Regardless of your current level of
sexual activity, please answer the following
question. If you prefer not to answer it,
please mark this box and go to the next
section.
Q1

I am satisfied with my sex life
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Please circle or mark one number per line to indicate your response as
it applies to the past 7 days.

EMOTIONAL WELL-BEING
Not at
all

I feel sad
I am satisfied with how I am coping
with my illness
I am losing hope in the fight against my
illness
I feel nervous
I worry about dying
I worry that my condition will get worse

A little
bit

Somewhat

Quite a
bit

Very
much

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

A little
bit

Somewhat

Quite a
bit

0

1

2

3

4

0

1

2

3

4

0
0
0
0

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

0

1

2

3

4

FUNCTIONAL WELL-BEING
Not at
all

I am able to work (include work at
home)
My work (include work at home) is
fulfilling
I am able to enjoy life
I have accepted my illness
I am sleeping well
I am enjoying the things I usually do for
fun
I am content with the quality of my life
right now

100

Very
much

Please circle or mark one number per line to indicate your response as
it applies to the past 7days.

ADDITIONAL CONCERNS
Not at
all

I have been short of breath
am self-conscious about the way I
dress
One or both of my arms are swollen or
tender
I feel sexually attractive
I am bothered by hair loss
I worry that other members of my
family might
someday get the same illness I have
I worry about the effect of stress on my
illness
I am bothered by a change in weight
I am able to feel like a woman
I have certain parts of my body where I
experience pain
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A little
bit

Somewhat

Quite a
bit

Very
much

0
0

1
1

2
2

3
3

4
4

0

1

2

3

4

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

0

1

2

3

4

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4
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Appendix G
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Appendix H
PHYSICAL ACTIVITY APPRAISAL INVENTORY (PAAI)

Directions: Using the 0-100 scale below, please rate how sure you are that you
can perform your usual physical activities regularly under the following
conditions. Physical activity refers to all activity at home, work, or leisure.
0
10
20
30
40
50
60
70
80
90
100
Cannot
do at all

Moderately
certain can do

Certain
can do

I am confident that I can perform my usual physical activities (includes all
activity at home, work, or leisure): (0-100)

1. When I am feeling tired _____
2. When I am feeling pressure from work or school ______
3. During bad weather ______
4. During or after experiencing personal problems ______
5. When I am feeling depressed ______
6. When I am feeling anxious ______
7. When I feel physical discomfort with an activity
8. When I have too much work to do at home ______
9. When I/we have visitors ______
10. When there are other interesting things to do _____
11. When I don’t have support from my family or friends ______
12. When I have other time commitments ______
13. When I do not feel well ______
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Adjunct Faculty/Guest Lecturer, Physical Therapist Assistant Program,
Sinclair Community College, Dayton, Ohio

2001 – 2005

Guest Lecturer, Master of Physical Therapy Program, Andrews
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1995 – 2001
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PROFESSIONAL ORGANIZATIONS
Member, American Physical Therapy Association (APTA)
Member, Orthopedic Section of APTA
Member, Women’s Health Section of APTA
Member, Oncology Section of APTA
HONORS AND AWARDS
Two-time performance recognition bonus, Miami Valley Hospital, 1997, 1998
Wittenberg University Scholar, 1985 – 1989
Mortar Board Senior Honorary 1989
GRANTS
Rehabilitation Sciences Doctoral Program Grant, University of Kentucky, $2500, 2009
PRESENTATIONS
Educational Session:
Levangie, PK, Fisher, MI, Perdomo, M, Kendig, T (February 2012) Oncology Section Task
Force on Breast Cancer Outcomes. Combined Sections Meeting, APTA, Chicago, IL.
Technical Session/Platform Presentations:
(Student names underlined)
Fisher, MI, Uhl, TL, Brown, C., Golden, K. A Comparison of Arm Function Between Long
Term Breast Cancer Survivors and Healthy Controls. Accepted to the January 2013
Combined Sections Meeting, American Physical Therapy Association.
Capilouto, GJ, Fisher, MI, Granger, D, Isaacs, K & Joyner, K. (November 2009) Nursing
Perspectives of Readiness to Bottle Feed in Preterm Infants. American Speech and
Hearing Association, New Orleans, LA.
Invited Presentations:
Fisher, MI. Oncology Rehabilitation for Therapists: A Focus on Breast Cancer.
West Central District Meeting of the Ohio Physical Therapy Association, October 2012.
Fisher, MI. Oncology Rehabilitation for Therapists: A Focus on Breast Cancer.
University of Findlay, March 2012.
Poster Presentations:
(Student names underlined)
Brahler, CJ, Donahoe-Fillmore, B, Fisher, MI, Anloague, PA. Critical Thinking and
Academic Performance are associated with NPTE Scores in Doctor of Physical Therapy
Program Graduates. Accepted for presentation at the Combined Sections Meeting,
American Physical Therapy Association, San Diego, CA (January 2013).
Brahler, CJ, Hess, NJ, Lorenzo, BM, Fisher, MI, Donahoe-Fillmore, B, Glenn, T.
Adolescents Engaged In At Least Five Hours Of Physical Activity Weekly Show
Numerous Health Benefits. American College of Sports Medicine Annual Meeting, San
Diego, CA (June, 2012).
Fisher, MI. A Systematic Review of the Effectiveness of Exercise on Arm Function in
Breast Cancer Survivors. Markey Cancer Research Day, University of Kentucky,
Lexington, KY (March 2011). First Place, Graduate Clinical Sciences Division.

121

Fisher, MI. A Systematic Review of the Effectiveness of Exercise on Arm Function in
Breast Cancer Survivors. Combined Sections Meeting, American Physical Therapy
Association, New Orleans, LA (February 2011).
Brahler, CJ, Donahoe-Fillmore, B, Fisher, MI. The Effects of Problem-based Learning on
Critical Thinking in Graduate Physical Therapy Students. Combined Sections Meeting,
American Physical Therapy Association, New Orleans, LA (February 2011).
Fisher, MI, Howell, D. An ICF-based model to empower and improve self-efficacy of
breast cancer survivors. Combined Sections Meeting, American Physical Therapy
Association, San Diego, CA (February 2010).
Donahoe-Fillmore, B, Brahler, CJ, Beasley, K, Fisher, MI, VanCleave, H, & Bowman, R.
The Effects of Home-Based vs Class-Based Pilates in Healthy College-Aged Females.
Combined Sections Meeting, American Physical Therapy Association, San Diego, CA
(February 2010).
PUBLICATIONS
Fisher, MI, Howell, D. The Power of Empowerment: An ICF-Based Model to Improve
Self-Efficacy and Upper Extremity Function of Survivors of Breast Cancer, Rehabilitation
Oncology, Vol 28, Number 3, November 2010.
Donahoe-Fillmore, B, Brahler, CJ, Fisher, MI, Beasley, K. The Effect of Yoga Postures
on Balance, Flexibility and Strength in Healthy High School Females, Journal of Women’s
Health Physical Therapy, Jan/Apr 2010.
Manuscripts in Press:
Fisher, MI, Levangie, PK. Oncology Section Taskforce on Breast Cancer Outcomes:
Scapular Assessment. Rehabilitation Oncology, Vol 30, No. 4, January 2013.
Levangie, PK, Fisher, MI. Oncology Section Taskforce on Breast Cancer Outcomes: An
Introduction. Rehabilitation Oncology, Vol 30, No. 4, January 2013.
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